EUR RADIOL 2021 10.1007/s00330-021-08094-3

Prediction of epithelial-to-mesenchymal transition molecular subtype using CT in gastric cancer

Cha¹, DI; Lee, J; Jeong, WK; Kim, ST; Kim, JH; Hong, JY; Kang, WK; Kim, KM; Kim, SW; Choi, D

CANCERS 2021 10.3390/cancers13102316

Validation of the Combined Biomarker for Prediction of Response to Checkpoint Inhibitor in Patients with Advanced Cancer

Kim¹, JC; Heo, YJ; Kang, SY; Lee, J; Kim, KM

NATURE 2021 10.1038/s41586-021-03515-1

ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma

Yen¹, I; Shanahan, F; Lee, J; Hong, YS; Shin, SJ; Moore, AR; Sudhamsu, J; Chang, MT; Bae, I; Dela Cruz, D; Hunsaker, T; Klijn, C; Liau, NPD; Lin, E; Martin, SE; Modrusan, Z; Piskol, R; Segal, E; Venkatanarayan, A; Ye, X; Yin, JP; Zhang, LX; Kim, JS; Lim, HS; Kim, KP; Kim, YJ; Han, HS; Lee, SJ; Kim, ST; Jung, M; Hong, YH; Noh, YS; Choi, M; Han, O; Nowicka, M; Srinivasan, S; Yan, YB; Kim, TW; Malek, S

JAMA ONCOL 2021 10.1001/jamaoncol.2021.0275

Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials

Chao¹, JS; Fuchs, CS; Shitara, K; Tabernero, J; Muro, K; Van Cutsem, E; Bang, YJ; De Vita, F; Landers, G; Yen, CJ; Chau, I; Elme, A; Lee, J; Ozguroglu, M; Catenacci, D; Yoon, HH; Chen, ER; Adelberg, D; Shih, CS; Shah, SK; Bhagia, P; Wainberg, ZA

J DERMATOL 2021 10.1111/1346-8138.15824

Clinical profile of cutaneous adverse events of immune checkpoint inhibitors in a single tertiary center

Park¹, JH; Yoon, D; Lee, J; Oh, SJ; Kim, HJ; Lee, JH; Lee, DY

ONCOLOGY-BASEL 2021 10.1159/000514404

Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer

Kim¹, H; Kim, J; Byeon, S; Jang, KT; Hong, JY; Lee, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST

ANN ONCOL 2021 10.1016/j.annonc.2020.11.017

A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial

Park¹, SH; Lim, DH; Sohn, TS; Lee, J; Zang, DY; Kim, ST; Kang, JH; Oh, SY; Hwang, IG; Ji, JH; Shin, DB; Yu, JI; Kim, KM; An, JY; Choi, MG; Lee, JH; Kim, S; Hong, JY; Park, JO; Park, YS; Lim, HY; Bae, JM; Kang, WK

ESMO OPEN 2021 10.1016/j.esmoop.2020.100002

Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment

Byeon¹, S; Cho, HJ; Jang, KT; Kwon, M; Lee, J; Kim, ST

NAT COMMUN 2021 10.1038/s41467-021-21299-w

Chromatin accessibility of circulating CD8(+) T cells predicts treatment response to PD-1 blockade in patients with gastric cancer

Shin¹, HM; Kim, G; Kim, S; Sim, JH; Choi, J; Kim, M; Kwon, M; Ye, SK; Lee, DS; Cho, SW; Kim, ST; Lee, J; Kim, HR

THER ADV MED ONCOL 2021 10.1177/1758835921992992

Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors

Kim¹, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Kim, ST

GENOME MED 2021 10.1186/s13073-021-00826-w

Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial

Kim¹, ST; Sa, JK; Oh, SY; Kim, K; Hong, JY; Kang, WK; Kim, KM; Lee, J

J CANCER 2021 10.7150/jca.49176

Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer

Kim¹, J; Kim, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST

CANCERS 2021 10.3390/cancers13010059

Impact of Radiotherapy on Kidney Function among Patients Who Received Adjuvant Treatment for Gastric Cancer: Logistic and Linear Regression Analyses

Park¹, JS; Il Yu, J; Lim, D; Nam, H; Kim, YI; Lee, J; Kang, WK; Park, SH; Kim, ST; Hong, JY; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM

J IMMUNOL 2020 10.4049/jimmunol.1901470

IL-7R alpha(low) CD8(+) T Cells from Healthy Individuals Are Anergic with Defective Glycolysis

Sim¹, JH; Kim, JH; Park, AK; Lee, J; Kim, KM; Shin, HM; Kim, M; Choi, K; Choi, EY; Kang, I; Lee, DS; Kim, HR

EXP MOL MED 2020 10.1038/s12276-020-00538-y

Tumor-promoting macrophages prevail in malignant ascites of advanced gastric cancer

Eum¹, HH; Kwon, M; Ryu, D; Jo, A; Chung, W; Kim, N; Hong, Y; Son, DS; Kim, ST; Lee, J; Lee, HO; Park, WY

CANCER IMMUNOL IMMUN 2020 10.1007/s00262-020-02794-3

Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab

Kim¹, N; Yu, JI; Park, HC; Yoo, GS; Choi, C; Hong, JY; Lim, HY; Lee, J; Choi, MS; Lee, JE; Kim, K

THER ADV MED ONCOL 2020 10.1177/1758835920965842

Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment

Lee¹, MS; Cho, HJ; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Cho, YB; Kim, ST

RADIOTHER ONCOL 2020 10.1016/j.radonc.2020.07.043

Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer Analysis of the ARTIST phase III trial

Yu¹, JI; Choi, C; Lee, J; Kang, WK; Park, SH; Kim, ST; Hong, JY; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, KM; Han, H; Kim, K; Nam, H; Lim, DH

JAMA ONCOL 2020 10.1001/jamaoncol.2020.3370

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer The KEYNOTE-062 Phase 3 Randomized Clinical Trial

Shitara¹, K; Van Cutsem, E; Bang, YJ; Fuchs, C; Wyrwicz, L; Lee, KW; Kudaba, I; Garrido, M; Chung, HC; Lee, J; Castro, HR; Mansoor, W; Braghiroli, MI; Karaseva, N; Caglevic, C; Villanueva, L; Goekkurt, E; Satake, H; Enzinger, P; Alsina, M; Benson, A; Chao, J; Ko, AH; Wainberg, ZA; Kher, U; Shah, S; Kang, SP; Tabernero, J

CANCER RES TREAT 2020 10.4143/crt.2020.173

A Multi-cohort Study of the Prognostic Significance of Microsatellite Instability or Mismatch Repair Status after Recurrence of Resectable Gastric Cancer

An¹, JY; Choi, YY; Lee, J; Hyung, WJ; Kim, KM; Noh, SH; Choi, MG; Cheong, JH

GASTRIC CANCER 2020 10.1007/s10120-020-01124-x

Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors

Kim¹, YY; Lee, J; Jeong, WK; Kim, ST; Kim, JH; Hong, JY; Kang, WK; Kim, KM; Sohn, I; Choi, D

GENOME MED 2020 10.1186/s13073-020-00776-9

Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions

Lin¹, W; Noel, P; Borazanci, EH; Lee, J; Amini, A; Han, IW; Heo, JS; Jameson, GS; Fraser, C; Steinbach, M; Woo, Y; Fong, Y; Cridebring, D; Von Hoff, DD; Park, JO; Han, HY

CURR ONCOL 2020 10.3747/co.27.6163

Severe cytomegalovirus gastritis after pembrolizumab in a patient with melanoma

Kim¹, H; Ha, SY; Kim, J; Kang, M; Lee, J

EXPERT OPIN INV DRUG 2020 10.1080/13543784.2020.1804855

Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors

Kim¹, S; Kim, S; Park, YS; Park, JO; Lim, HY; Ahn, JS; Lee, J; Sun, JM; Kang, WK; Han, R; Kim, J; Ahn, MJ

J CLIN ONCOL 2020 10.1200/JCO.19.01834

Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma

Catenacci¹, DVT; Rasco, D; Lee, J; Rha, SY; Lee, KW; Bang, YJ; Bendell, J; Enzinger, P; Marina, N; Xiang, H; Deng, W; Powers, J; Wainberg, ZA

THER ADV MED ONCOL 2020 10.1177/1758835920926796

First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients

Kim¹, ST; Hong, JY; Park, SH; Park, JO; Park, YW; Park, N; Lee, H; Hong, SH; Lee, SJ; Song, SW; Kim, K; Park, YS; Lim, HY; Kang, WK; Nam, H; Lee, JW; Park, K; Kim, KM; Lee, J

PATHOL RES PRACT 2020 10.1016/j.prp.2020.152941

CDH1 mutations in gastric cancers are not associated with family history

Choi¹, S; Jang, J; Heo, YJ; Kang, SY; Kim, ST; Lee, J; Kang, WK; Kim, JW; Kim, KM

Transl Cancer Res 2020 10.21037/tcr-19-1876

Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer

Hong¹, JY; An, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, KM; Kang, WK; Kim, ST

Transl Cancer Res 2020 10.21037/tcr.2020.04.07

Antitumor activity and safety of sirolimus for solid tumors with PIK3CA mutations: A multicenter, open-label, prospective single-arm study (KM 02-01, KCSG UN17-16)

Byeon¹, S; Kang, MJ; Choi, YJ; Kim, YJ; Kim, M; Yun, J; Yi, SY; Kim, JY; Kim, ST; Lee, J

CANCERS 2020 10.3390/cancers12040943

Outcomes of Radiotherapy for Mesenchymal and Non-Mesenchymal Subtypes of Gastric Cancer

Yu¹, JI; Park, HC; Lee, J; Choi, C; Kang, WK; Park, SH; Kim, ST; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, KM; Han, H; Kim, K; Kim, S; Lim, DH

PATHOL RES PRACT 2020 10.1016/j.prp.2020.152881

High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features

Liu¹, XQ; Choi, MG; Kim, K; Kim, KM; Kim, ST; Park, SH; Cristescu, R; Peter, S; Lee, J

PATHOL RES PRACT 2020 10.1016/j.prp.2020.152878

High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers

Hur¹, JY; Chao, J; Kim, K; Kim, ST; Kim, KM; Klempner, SJ; Lee, J

TARGET ONCOL 2020 10.1007/s11523-020-00706-0

Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study

Byeon¹, S; Hong, JY; Lee, J; Nam, DH; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST

INT J MOL SCI 2020 10.3390/ijms21082825

Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells

Kim¹, H; Lee, SJ; Lee, IK; Min, SC; Sung, HH; Jeong, BC; Lee, J; Park, SH

JAMA NETW OPEN 2020 10.1001/jamanetworkopen.2020.3652

Association Between Spatial Heterogeneity Within Nonmetastatic Gastroesophageal Adenocarcinomas and Survival

Chao¹, J; Bedell, V; Lee, J; Li, MS; Chu, PG; Yuan, YC; Zhao, D; Klempner, SJ; Lin, RJ

TARGET ONCOL 2020 10.1007/s11523-020-00713-1

Impact of Prior Ramucirumab Use on Treatment Outcomes of Checkpoint Inhibitors in Advanced Gastric Cancer Patients

Kim¹, J; Byeon, S; Kim, H; Yeo, JH; Hong, JY; Lee, J; Lim, HY; Kang, WK; Kim, ST

Clin Pharmacol Drug Dev 2020 10.1002/cpdd.788

Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAF(V600) Mutation-Positive Malignancies

Zhang¹, WJ; McIntyre, C; Riehl, T; Forbes, H; Bertran, E; Choi, HJ; Lee, DH; Lee, J

ESMO OPEN 2020 10.1136/esmoopen-2020-000670

Clinical scoring system for the prediction of survival of patients with advanced gastric cancer

Kim¹, J; Hong, JY; Kim, ST; Park, SH; Jekal, SY; Choi, JS; Chang, DK; Kang, WK; Seo, SW; Lee, J

Front Oncol 2020 10.3389/fonc.2020.00314

Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer

Kim¹, J; Kim, B; Kang, SY; Heo, YJ; Park, SH; Kim, ST; Kang, WK; Lee, J; Kim, KM

PATHOL RES PRACT 2020 10.1016/j.prp.2020.152820

TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer

Hong¹, JY; Kim, HJ; Kim, K; Hong, J; Kim, JE; Byeon, SJ; Lee, IK; Kim, KM; Shim, M; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, J; Kang, WK

Genome Med 2020 10.1186/s13073-020-0717-8

Comprehensive pharmacogenomic characterization of gastric cancer

Sa¹, JK; Hong, JY; Lee, IK; Kim, JS; Sim, MH; Kim, HJ; An, JY; Sohn, TS; Lee, JH; Bae, JM; Kim, S; Kim, KM; Kim, ST; Park, SH; Park, JO; Lim, HY; Kang, WK; Her, NG; Lee, Y; Cho, HJ; Shin, YJ; Kim, M; Koo, H; Kim, M; Seo, YJ; Kim, JY; Choi, MG; Nam, DH; Lee, J

PLoS One 2020 10.1371/journal.pone.0228848

Tc-99m-MIBI uptake as a marker of mitochondrial membrane potential in cancer cells and effects of MDR1 and verapamil

Park¹, JW; Hong, SP; Lee, JH; Moon, SH; Cho, YS; Jung, KH; Lee, J; Lee, KH

CLIN CANCER RES 2020 10.1158/1078-0432.CCR-19-2443

Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Kelly¹, RJ; Lee, J; Bang, YJ; Almhanna, K; Blum-Murphy, M; Catenacci, DVT; Chung, HC; Wainberg, ZA; Gibson, MK; Lee, KW; Bendell, JC; Denlinger, CS; Chee, CE; Omori, T; Leidner, R; Lenz, HJ; Chao, Y; Rebelatto, MC; Brohawn, PZ; He, P; McDevitt, J; Sheth, S; Englert, JM; Ku, GY

TARGET ONCOL 2020 10.1007/s11523-019-00691-z

Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study

Kim¹, ST; Hong, JY; Lee, JY; Park, JO; Lim, HY; Kang, WK; Park, YS

VIRCHOWS ARCH 2020 10.1007/s00428-019-02653-2

PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation

Kim¹, HN; Jang, J; Heo, YJ; Kim, B; Jung, HR; Jang, Y; Kang, SY; Kim, ST; Lee, JY; Kang, WK; Kim, KM

Front Oncol 2020 10.3389/fonc.2020.00225

A Pilot Study of Baseline Spatial Genomic Heterogeneity in Primary Gastric Cancers Using Multi-Region Endoscopic Sampling

Chao¹, JS; Lee, J; Kim, K; Kang, SY; Lee, T; Kim, KM; Kim, ST; Klempner, SJ; Lee, H

PATHOL RES PRACT 2020 10.1016/j.prp.2019.152734

Correlation between RICTOR overexpression and amplification in advanced solid tumors

Bang¹, H; Ahn, S; Kim, EJ; Kim, ST; Park, H; Lee, J; Kim, KM

EJSO-EUR J SURG ONC 2020 10.1016/j.ejso.2019.08.025

Prognostic value of mismatch repair deficiency in patients with advanced gastric cancer, treated by surgery and adjuvant 5-fluorouracil and leucovorin chemoradiotherapy

Kim¹, SM; An, JY; Byeon, SJ; Lee, J; Kim, KM; Choi, MG; Lee, JH; Sohn, TS; Moon, J; Kim, S

BMC OPHTHALMOL 2020 10.1186/s12886-019-1285-9

Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors

Shin¹, E; Lim, DH; Han, JS; Nam, D; Park, K; Ahn, MJ; Kang, WK; Lee, JY; Ahn, JS; Lee, SH; Sun, JM; Jung, HA; Chung, TY

RESP MED 2020 10.1016/j.rmed.2019.105853

Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors

Im¹, Y; Lee, J; Kim, SJ; Koh, WJ; Jhun, BW; Lee, SH

J ONCOL 2020 10.1155/2020/4659062

Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers

Lee¹, SJ; Hong, JY; Kim, K; Kim, KM; Kang, SY; Lee, T; Kim, ST; Park, SH; Park, YS; Lim, HY; Kang, WK; Lee, J; Park, JO

CLIN CANCER RES 2019 10.1158/1078-0432.CCR-19-1704

Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma

Maron¹, SB; Chase, LM; Lomnicki, S; Kochanny, S; Moore, KL; Joshi, SS; Landron, S; Johnson, J; Kiedrowski, LA; Nagy, RJ; Lanman, RB; Kim, ST; Lee, J; Catenacci, DVT

MOL BIOL REP 2019 10.1007/s11033-019-05019-8

Anti-leukemic effects of simvastatin on NRAS(G12D) mutant acute myeloid leukemia cells

Jang¹, J; Lee, J; Jang, JH; Jung, CW; Park, S

CLIN CANCER RES 2019 10.1158/1078-0432.CCR-19-1324

Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel

Willis¹, J; Lefterova, MI; Artyomenko, A; Kasi, PM; Nakamura, Y; Mody, K; Catenacci, DVT; Fakih, M; Barbacioru, C; Zhao, J; Sikora, M; Fairclough, SR; Lee, H; Kim, KM; Kim, ST; Kim, J; Gavino, D; Benavides, M; Peled, N; Nguyen, T; Cusnir, M; Eskander, RN; Azzi, G; Yoshino, T; Banks, KC; Raymond, VM; Lanman, RB; Chudova, DI; Talasaz, A; Kopetz, S; Lee, J; Odegaard, JI

SCI REP-UK 2019 10.1038/s41598-019-52180-y

Acral malignant melanoma; emphasis on the primary metastasis and the usefulness of preoperative ultrasound for sentinel lymph node metastasis

Kwon¹, MR; Choi, SH; Jang, KT; Kim, JH; Mun, GH; Lee, J; Lee, DY

TRANSL ONCOL 2019 10.1016/j.tranon.2019.07.017

Cancer Panel Assay for Precision Oncology Clinic: Results from a 1-Year Study

Kwon¹, D; Kim, B; Shin, HC; Kim, EJ; Ha, SY; Jang, KT; Kim, ST; Lee, J; Kang, WK; Park, JO; Kim, KM

Front Oncol 2019 10.3389/fonc.2019.01327

Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening

Lim¹, SH; Sa, JK; Lee, DW; Kim, J; Kim, ST; Park, SH; Ku, B; Park, JO; Park, YS; Lim, H; Kang, WK; Nam, DH; Lee, J

Cancer Med 2019 10.1002/cam4.2570

Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma

Yu¹, JI; Lee, SJ; Lee, J; Lim, HY; Paik, SW; Yoo, GS; Choi, C; Park, HC

INT J CANCER 2019 10.1002/ijc.32228

Bridging genomics and phenomics of gastric carcinoma

Cho¹, J; Ahn, S; Son, DS; Kim, NKD; Lee, KW; Kim, S; Lee, J; Park, SH; Park, JO; Kang, WK; An, JY; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Kim, KM

J Cancer 2019 10.7150/jca.37610

Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial

Kim¹, ST; Oh, SY; Lee, J; Kang, JH; Lee, HW; Lee, MA; Sohn, BS; Hong, JH; Park, YS; Park, JO; Lim, HY

TUMORI 2019 10.1177/0300891618792476

Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in rectal cancer patients following neoadjuvant chemoradiotherapy

Kim¹, TG; Park, W; Kim, H; Choi, DH; Park, HC; Kim, SH; Cho, YB; Yun, SH; Kim, HC; Lee, WY; Lee, J; Kang, KM

SCI REP-UK 2019 10.1038/s41598-019-51981-5

Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients

Bray¹, SM; Lee, J; Kim, ST; Hur, JY; Ebert, PJ; Calley, JN; Wulur, IH; Gopalappa, T; Wong, SS; Qian, HR; Ting, JC; Liu, JG; Willard, MD; Novosiadly, RD; Park, YS; Park, JO; Lim, HY; Kang, WK; Aggarwal, A; Kim, HC; Reinhard, C

J IMMUNOTHER 2019 10.1097/CJI.0000000000000283

LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target

Lee¹, SJ; Byeon, SJ; Lee, J; Park, SH; Park, JO; Park, YS; Kang, WK; Lim, HY; Kim, KM; Kim, ST

CANCER DISCOV 2019 10.1158/2159-8290.CD-19-0442

Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial

Lee¹, J; Kim, ST; Kim, K; Lee, H; Kozarewa, I; Mortimer, PGS; Odegaard, JI; Harrington, EA; Lee, J; Lee, T; Oh, SY; Kang, JH; Kim, JH; Kim, Y; Ji, JH; Kim, YS; Lee, KE; Kim, J; Sohn, TS; An, JY; Choi, MG; Lee, JH; Bae, JM; Kim, S; Kim, JJ; Min, YW; Min, BH; Kim, NKD; Luke, S; Kim, YH; Hong, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Talasaz, A; Hollingsworth, SJ; Kim, KM; Kang, WK

SCI REP-UK 2019 10.1038/s41598-019-50574-6

Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab

Eun¹, Y; Kim, IY; Sun, JM; Lee, J; Cha, HS; Koh, EM; Kim, H; Lee, J

ANTICANCER RES 2019 10.21873/anticanres.13785

Clinical Outcomes and the Role of Adjuvant Concurrent Chemoradiation Therapy in D2-resected LN-positive Young Patients (<= 45 Years) With Gastric Cancer

Yu¹, JI; Lim, DH; Lee, J; Kang, WK; Park, SH; Park, JO; Lim, HY; Kim, ST; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, HS; Ahn, S

Transl Cancer Res 2019 10.21037/tcr.2019.09.27

Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs

Cho¹, JH; Kim, SY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST

BMC CANCER 2019 10.1186/s12885-019-6030-5

Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody

Lee¹, J; Lee, SJ; Kim, K; Kim, ST; Lee, J

PATHOL RES PRACT 2019 10.1016/j.prp.2019.152434

CCNE1 amplification is associated with liver metastasis in gastric carcinoma

Kim¹, B; Shin, HC; Heo, YJ; Ha, SY; Jang, KT; Kim, ST; Kang, WK; Lee, J; Kim, KM

SCI REP-UK 2019 10.1038/s41598-019-46216-6

Reproduction of molecular subtypes of gastric adenocarcinoma by transcriptome sequencing of archival tissue

Heo¹, YJ; Park, C; DoyeongYu; Lee, J; Kim, KM

CANCER RES TREAT 2019 10.4143/crt.2018.401

Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node-Positive Gastric Cancer Treated with Different Adjuvant Protocols

Yu¹, JI; Lim, D; Lee, J; Kang, WK; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, SJ; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Rae, JM; Yoo, H; Kim, K

Am J Transl Res 2019

Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification

Kim¹, ST; Lee, IK; Rom, E; Sirkis, R; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Yayon, A; Lee, J

J MOL DIAGN 2019 10.1016/j.jmoldx.2019.02.007

Tumor Heterogeneity Index to Detect Human Epidermal Growth Factor Receptor 2 Amplification by Next-Generation Sequencing A Direct Comparison Study with Immunohistochemistry

Choi¹, S; Chu, J; Kim, B; Ha, SY; Kim, ST; Lee, J; Kang, WK; Han, H; Sohn, I; Kim, KM

CANCER RES TREAT 2019 10.4143/crt.2018.379

A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients

Kim¹, Y; Kim, TW; Han, SW; Ahn, JB; Kim, ST; Lee, J; Park, JO; Park, YS; Lim, HY; Kang, WK

J Cancer 2019 10.7150/jca.30355

The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma

Yoon¹, SE; Kim, JH; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST

J Cancer 2019 10.7150/jca.30257

High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer

Kim¹, Y; Byeon, SJ; Hur, J; Lee, K; Kim, D; Ahn, JH; Lee, SH; You, WK; Kim, ST; Park, SH; Kang, WK; Kim, KM; Lee, J

ONCOLOGY-BASEL 2019 10.1159/000499628

Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial

Miceli¹, R; An, J; Di Bartolomeo, M; Morano, F; Kim, ST; Park, SH; Choi, MG; Lee, JH; Raimondi, A; Fuca, G; Sohn, TS; Bae, JM; Kim, S; Lim, DH; Kang, WK; Kim, KM; Pietrantonio, F; Lee, J

ANN ONCOL 2019 10.1093/annonc/mdz058

Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial

Kim¹, ST; Kang, JH; Lee, J; Lee, HW; Oh, SY; Jang, JS; Lee, MA; Sohn, BS; Yoon, SY; Choi, HJ; Hong, JH; Kim, MJ; Kim, S; Park, YS; Park, JO; Lim, HY

TRANSL ONCOL 2019 10.1016/j.tranon.2018.12.009

Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial

Kim¹, ST; Lee, S; Park, M; Park, SH; Park, JO; Lim, HY; Park, YS; Kang, WK; Gangolli, EA; Shin, H; Kim, KM; Hollingsworth, SJ; Mortimer, PGS; Lee, J

Front Oncol 2019 10.3389/fonc.2019.00212

Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort

Lee¹, J; Franovic, A; Shiotsu, Y; Kim, ST; Kim, KM; Banks, KC; Raymond, VM; Lanman, RB

PLoS One 2019 10.1371/journal.pone.0215080

Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system

Cho¹, JH; Kim, JS; Kim, ST; Hong, JY; Park, JO; Park, YS; Nam, DH; Lee, DW; Lee, J

J Cancer 2019 10.7150/jca.29106

The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer

Yoon¹, SE; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST

SCI REP-UK 2019 10.1038/s41598-019-41098-0

Intratumor heterogeneity inferred from targeted deep sequencing as a prognostic indicator

Oh¹, BY; Shin, HT; Yun, JW; Kim, KT; Kim, J; Bae, JS; Cho, YB; Lee, WY; Yun, SH; Park, YA; Park, YH; Im, YH; Lee, J; Joung, JG; Kim, HC; Park, WY

CANCER CHEMOTH PHARM 2019 10.1007/s00280-018-3753-y

Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer

Oh¹, SY; Lee, S; Huh, SJ; Lee, J; Kim, ST; Park, SH; Lim, HY; Kang, WK; Kang, BW; Kim, JG; Lee, HJ; Kim, JH; Kang, JH; Kim, H

PATHOL RES PRACT 2019 10.1016/j.prp.2018.11.010

MET is overexpressed in microsatellite instability-high gastric carcinoma

Sim¹, J; Heo, YJ; Bae, H; Shin, HC; Kim, B; Cho, J; Kim, ST; Lee, J; Kang, WK; Kim, KM

ANN ONCOL 2019 10.1093/annonc/mdy550

Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer

Sundar¹, R; Huang, KK; Qamra, A; Kim, KM; Kim, ST; Kang, WK; Tan, ALK; Lee, J; Tan, P

J IMMUNOTHER CANCER 2019 10.1186/s40425-019-0508-1

Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

Chung¹, HC; Arkenau, HT; Lee, J; Rha, SY; Oh, DY; Wyrwicz, L; Kang, YK; Lee, KW; Infante, JR; Lee, SS; Kemeny, M; Keilholz, U; Melichar, B; Mita, A; Plummer, R; Smith, D; Gelb, AB; Xiong, HL; Hong, J; Chand, V; Safran, H

Oncoimmunology 2019 10.1080/2162402X.2018.1544442

PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer

Angell¹, HK; Lee, J; Kim, KM; Kim, K; Kim, ST; Park, SH; Kang, WK; Sharpe, A; Ogden, J; Davenport, A; Hodgson, DR; Barrett, JC; Kilgour, E

CANCER GENET-NY 2019 10.1016/j.cancergen.2019.01.004

Genomic landscape of synchronous tubulovillous adenoma and multiple non-familial colon cancers from a single patient

Kim¹, K; Choi, SH; Lee, J; Lee, WS

OncoTargets and therapy 2019 10.2147/OTT.S187621

The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice

Yoon¹, SE; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST

CANCER RES TREAT 2019 10.4143/crt.2018.132

Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients

Lee¹, SH; Lee, B; Shim, JH; Lee, KW; Md, JWY; Kim, SY; Kim, TY; Kim, YH; Ko, YH; Chung, HC; Yu, CS; Lee, J; Rha, SY; Kim, TW; Jung, KH; Im, SA; Moon, HG; Cho, S; Kang, JH; Kim, J; Kim, SK; Ryu, HS; Ha, SY; Il Kim, J; Chung, YJ; Kim, C; Kim, HL; Park, WY; Noh, DY; Park, K

J Gastric Cancer 2018 10.5230/jgc.2018.18.e34

Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial

Kim¹, Y; Kim, KM; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Lee, SJ; Kim, ST; Lee, J; Park, JO; Park, YS; Lim, HY; Kang, WK; Park, SH

RADIOTHER ONCOL 2018 10.1016/j.radonc.2018.07.002

Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer

Yu¹, JI; Lim, DH; Lee, J; Kang, WK; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, SJ; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, HS; Ahn, S

GASTRIC CANCER 2018 10.1007/s10120-018-0851-9

Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes

Sundar¹, R; Qamra, A; Tan, ALK; Zhang, SL; Ng, CCY; Teh, BT; Lee, J; Kim, KM; Tan, P

BMC CANCER 2018 10.1186/s12885-018-4995-0

Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line

Kim¹, ST; Kim, SY; Lee, J; Kim, K; Park, SH; Park, YS; Lim, HY; Kang, WK; Park, JO

NAT GENET 2018 10.1038/s41588-018-0209-6

Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy

Lee¹, JK; Liu, ZQ; Sa, JK; Shin, S; Wang, JG; Bordyuh, M; Cho, H; Elliott, O; Chu, T; Choi, SW; Rosenbloom, DIS; Lee, IH; Shin, YJ; Kang, HJ; Kim, D; Kim, SY; Sim, MH; Kim, J; Lee, T; Seo, YJ; Shin, H; Lee, M; Kim, SH; Kwon, YJ; Oh, JW; Song, M; Kim, M; Kong, DS; Choi, JW; Seol, HJ; Lee, JI; Kim, ST; Park, JO; Kim, KM; Song, SY; Lee, JW; Kim, HC; Lee, JE; Choi, MG; Seo, SW; Shim, YM; Zo, JI; Jeong, BC; Yoon, Y; Ryu, GH; Kim, NKD; Bae, JS; Park, WY; Lee, J; Verhaak, RGW; Iavarone, A; Lee, J; Rabadan, R; Nam, DH

NAT MED 2018 10.1038/s41591-018-0101-z

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

Kim¹, ST; Cristescu, R; Bass, AJ; Kim, KM; Odegaard, JI; Kim, K; Liu, XQ; Sher, XW; Jung, H; Lee, M; Lee, S; Park, SH; Park, JO; Park, YS; Lim, HY; Lee, H; Choi, M; Talasaz, A; Kang, PS; Cheng, J; Loboda, A; Lee, J; Kang, WK

CLIN COLORECTAL CANC 2018 10.1016/j.clcc.2018.02.013

c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival

Lee¹, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST

SCI REP-UK 2018 10.1038/s41598-018-32299-0

Computational measurement of tumor immune microenvironment in gastric adenocarcinomas

Chang¹, YH; Heo, YJ; Cho, J; Song, SY; Lee, J; Kim, KM

J Cancer 2018 10.7150/jca.26068

Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation

Lee¹, T; Kim, K; Lee, J; Park, SH; Park, YS; Lim, HY; Kang, WK; Park, JO; Kim, ST

J CLIN PHARMACOL 2018 10.1002/jcph.1111

Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Digoxin in Patients With BRAF(V600) Mutation-Positive Metastatic Malignancy

Zhang¹, WJ; McIntyre, C; Kuhn, M; Forbes, H; Kim, TM; Lee, J; Demidov, L; Colburn, D

NAT GENET 2018 10.1038/s41588-018-0138-4

A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors

Alvarez¹, MJ; Subramaniam, PS; Tang, LH; Grunn, A; Aburi, M; Rieckhof, G; Komissarova, EV; Hagan, EA; Bodei, L; Clemons, PA; Dela Cruz, FS; Dhall, D; Diolaiti, D; Fraker, DA; Ghavami, A; Kaemmerer, D; Karan, C; Kidd, M; Kim, KM; Kim, HC; Kunju, LP; Langel, U; Li, Z; Lee, J; Li, H; LiVolsi, V; Pfragner, R; Rainey, AR; Realubit, RB; Remotti, H; Regberg, J; Roses, R; Rustgi, A; Sepulveda, AR; Serra, S; Shi, CJ; Yuan, XP; Barberis, M; Bergamaschi, R; Chinnaiyan, AM; Detre, T; Ezzat, S; Frilling, A; Hommann, M; Jaeger, D; Kim, MK; Knudsen, BS; Kung, AL; Leahy, E; Metz, DC; Milsom, JW; Park, YS; Reidy-Lagunes, D; Schreiber, S; Washington, K; Wiedenmann, B; Modlin, I; Califano, A

J Cancer 2018 10.7150/jca.26256

NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines

Kim¹, SY; Oh, SO; Kim, K; Lee, J; Kang, S; Kim, KM; Lee, W; Kim, ST; Nam, DN

J Cancer 2018 10.7150/jca.24948

Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial

Lim¹, SW; Lee, S; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST

CLIN COLORECTAL CANC 2018 10.1016/j.clcc.2018.01.005

Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer

Lee¹, J; Kim, ST; Park, S; Lee, S; Park, SH; Park, JO; Lim, HY; Ahn, H; Bok, H; Kim, KM; Ahn, MJ; Kang, WK; Park, YS

ANN SURG ONCOL 2018 10.1245/s10434-018-6434-5

Adjuvant Chemotherapy Versus Chemoradiotherapy Versus Surgery Alone for Early Gastric Cancer with One or Two Lymph Node Metastasis

Kim¹, SM; An, JY; Lee, J; Sohn, TS; Kim, S

ANN ONCOL 2018 10.1093/annonc/mdy090

RET fusions in a small subset of advanced colorectal cancers at risk of being neglected

Pietrantonio¹, F; Di Nicolantonio, F; Schrock, AB; Lee, J; Morano, F; Fuca, G; Nikolinakos, P; Drilon, A; Hechtman, JF; Christiansen, J; Gowen, K; Frampton, GM; Gasparini, P; Rossini, D; Gigliotti, C; Kim, ST; Prisciandaro, M; Hodgson, J; Zaniboni, A; Chiu, VK; Milione, M; Patel, R; Miller, V; Bardelli, A; Novara, L; Wang, L; Pupa, SM; Sozzi, G; Ross, J; Di Bartolomeo, M; Bertotti, A; Ali, S; Trusolino, L; Falcone, A; de Braud, F; Cremolini, C

NAT COMMUN 2018 10.1038/s41467-018-04179-8

Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype

Oh¹, SC; Sohn, BH; Cheong, JH; Kim, SB; Lee, JE; Park, KC; Lee, SH; Park, JL; Park, YY; Lee, HS; Jang, HJ; Park, ES; Kim, SC; Heo, J; Chu, IS; Jang, YJ; Mok, YJ; Jung, W; Kim, BH; Kim, A; Cho, JY; Lim, JY; Hayashi, Y; Song, SM; Elimova, E; Estralla, JS; Lee, JH; Bhutani, MS; Lu, YL; Liu, WB; Lee, J; Kang, WK; Kim, S; Noh, SH; Mills, GB; Kim, SY; Ajani, JA; Lee, JS

MOL CANCER THER 2018 10.1158/1535-7163.MCT-17-0535

MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis

Kim¹, HK; Lee, I; Bang, H; Kim, HC; Lee, WY; Yun, SH; Lee, J; Lee, SJ; Park, YS; Kim, KM; Kang, WK

ANN ONCOL 2018 10.1093/annonc/mdy034

Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+gastric cancer patients

Kim¹, ST; Banks, KC; Pectasides, F; Kim, SY; Kim, K; Lanman, RB; Talasaz, A; An, J; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, NKD; Park, W; Lee, H; Bass, AJ; Kim, K; Kang, WK; Lee, J

J Cancer 2018 10.7150/jca.25132

The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer

Kim¹, ST; Kim, HK; Lee, J; Park, SH; Lim, HY; Park, YS; Kang, WK; Park, JO

TRANSL ONCOL 2018 10.1016/j.tranon.2018.01.007

The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer

Lee¹, SJ; Kim, JE; Kim, ST; Lee, J; Park, SH; Park, JO; Kang, WK; Park, YS; Lim, HY

TRANSL ONCOL 2018 10.1016/j.tranon.2017.10.008

Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract

Lee¹, JY; Kim, K; Sung, HH; Jeon, HG; Jeong, BC; Seo, SI; Jeon, SS; Lee, HM; Choi, HY; Kwon, GY; Kim, KM; Lee, J; Lim, HY; Park, SH

J GYNECOL ONCOL 2018 10.3802/jgo.2018.29.e3

Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study

Kim¹, HJ; Kim, Y; Lee, SJ; Lee, J; Park, SH

CANCER RES TREAT 2018 10.4143/crt.2016.535

Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study

Choi¹, Y; Yun, MS; Lim, SH; Lee, J; Ahn, JH; Kim, YJ; Park, KH; Park, YS; Lim, HY; An, H; Suh, DC; Kim, YH

CANCER DISCOV 2018 10.1158/2159-8290.CD-17-0395

Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma

Pectasides¹, E; Stachler, MD; Derks, S; Liu, Y; Maron, S; Islam, M; Alpert, L; Kwak, H; Kindler, H; Polite, B; Sharma, MR; Allen, K; O'Day, E; Lomnicki, S; Maranto, M; Kanteti, R; Fitzpatrick, C; Weber, C; Setia, N; Xiao, SY; Hart, J; Nagy, RJ; Kim, KM; Choi, MG; Min, BH; Nason, KS; O'Keefe, L; Watanabe, M; Baba, H; Lanman, R; Agoston, AT; Oh, DJ; Dunford, A; Thorner, AR; Ducar, MD; Wollison, BM; Coleman, HA; Ji, Y; Posner, MC; Roggin, K; Turaga, K; Chang, P; Hogarth, K; Siddiqui, UD; Gelrud, A; Ha, G; Freeman, SS; Rhoades, J; Reed, S; Gydush, G; Rotem, D; Davison, J; Imamura, Y; Adalsteinsson, V; Lee, J; Bass, AJ; Catenacci, DV

YONSEI MED J 2018 10.3349/ymj.2018.59.1.28

Protective Effects of Female Reproductive Factors on Lauren Intestinal-Type Gastric Adenocarcinoma

Kim¹, SM; Min, BH; Lee, J; An, JY; Lee, JH; Sohn, TS; Bae, JM; Kim, JJ; Kang, WK; Kim, S; Choi, MG

J NATL CANCER I 2017 10.1093/jnci/djx089

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer

Pietrantonio¹, F; Di Nicolantonio, F; Schrock, AB; Lee, J; Tejpar, S; Sartore-Bianchi, A; Hechtman, JF; Christiansen, J; Novara, L; Tebbutt, N; Fuca, G; Antoniotti, C; Kim, ST; Murphy, D; Berenato, R; Morano, F; Sun, J; Min, BS; Stephens, PJ; Chen, M; Cremolini, C

ONCOTARGET 2017 10.18632/oncotarget.22394

MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines

Kim¹, JE; Kim, Y; Li, G; Kim, ST; Kim, K; Park, SH; Park, JO; Park, YS; Lim, HY; Lee, H; Sohn, TS; Kim, KM; Kang, WK; Lee, J

INVEST NEW DRUG 2017 10.1007/s10637-017-0463-y

Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors

Lee¹, SJ; Lee, SY; Lee, WS; Yoo, JS; Sun, JM; Lee, J; Park, SH; Park, JO; Ahn, MJ; Lim, HY; Kang, WK; Park, YS

ONCOTARGET 2017 10.18632/oncotarget.18182

Correlation between MEK signature and Ras gene alteration in advanced gastric cancer

Ahn¹, S; Brant, R; Sharpe, A; Dry, JR; Hodgson, DR; Kilgour, E; Kim, K; Kim, ST; Park, SH; Kang, WK; Kim, KM; Lee, J

NAT COMMUN 2017 10.1038/s41467-017-01470-y

Prevalence and detection of low-allele-fraction variants in clinical cancer samples

Shin¹, HT; Choi, YL; Yun, JW; Kim, NKD; Kim, SY; Jeon, HJ; Nam, JY; Lee, C; Ryu, D; Kim, SC; Park, K; Lee, E; Bae, JS; Son, DS; Joung, JG; Lee, J; Kim, ST; Ahn, MJ; Lee, SH; Ahn, JS; Lee, WY; Oh, BY; Park, YH; Lee, JE; Lee, KH; Kim, HC; Kim, KM; Im, YH; Park, K; Park, PJ; Park, WY

ONCOTARGET 2017 10.18632/oncotarget.3750

MerTK is a novel therapeutic target in gastric cancer

Yi¹, JH; Jang, J; Cho, J; Do, IG; Hong, M; Kim, ST; Kim, KM; Lee, S; Park, SH; Park, JO; Park, YS; Kang, WK; Lim, HY; Lee, J

Oncoimmunology 2017 10.1080/2162402X.2017.1356150

Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity

Park¹, C; Cho, J; Lee, J; Kang, SY; An, JY; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Kim, ST; Park, SH; Park, JO; Kang, WK; Sohn, I; Jung, SH; Kang, MS; Kim, KM

ONCOLOGIST 2017 10.1634/theoncologist.2017-0020

Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials

Kim¹, ST; Kim, KM; Kim, NKD; Park, JO; Ahn, S; Yun, JW; Kim, KT; Park, SH; Park, PJ; Kim, HC; Sohn, TS; Il Choi, D; Cho, JH; Heo, JS; Kwon, W; Lee, H; Min, BH; Hong, SN; Park, YS; Lim, HY; Kang, WK; Park, WY; Lee, J

Clin Transl Oncol 2017 10.1007/s12094-017-1662-x

Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma

Cho¹, J; Kim, SY; Kim, YJ; Sim, MH; Kim, ST; Kim, NKD; Kim, K; Park, W; Kim, JH; Jang, KT; Lee, J

PLoS One 2017 10.1371/journal.pone.0185826

Unforeseen clonal evolution of tumor cell population in recurrent and metastatic dermatofibrosarcoma protuberans

Oh¹, E; Jeong, HM; Kwon, MJ; Ha, SY; Park, HK; Song, JY; Kim, YJ; Choi, JS; Lee, EH; Lee, J; Choi, YL; Shin, YK

ONCOTARGET 2017 10.18632/oncotarget.18168

The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs

Kim¹, HK; Ha, SY; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST

ONCOTARGET 2017 10.18632/oncotarget.20492

Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy

Kim¹, ST; Klempner, SJ; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Lee, J

ONCOTARGET 2017 10.18632/oncotarget.19985

Development of mesenchymal subtype gene signature for clinical application in gastric cancer

Lee¹, J; Cristescu, R; Kim, KM; Kim, K; Kim, ST; Park, SH; Kang, WK

CLIN CANCER RES 2017 10.1158/1078-0432.CCR-16-2211

Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project

Sohn¹, BH; Hwang, JE; Jang, HJ; Lee, HS; Oh, SC; Shim, JJ; Lee, KW; Kim, EH; Yim, SY; Lee, SH; Cheong, JH; Jeong, W; Cho, JY; Kim, J; Chae, J; Lee, J; Kang, WK; Kim, S; Noh, SH; Ajani, JA; Lee, JS

TRANSL ONCOL 2017 10.1016/j.tranon.2017.03.001

Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2-Amplified Gastric Cancer Patient-Derived Cell Model

Jang¹, J; Kim, HK; Bang, H; Kim, ST; Kim, SY; Park, SH; Lim, HY; Kang, WK; Lee, J; Kim, KM

Appl Immunohistochem Mol Morphol 2017 10.1097/PAI.0000000000000360

Detecting Gene Rearrangements in Patient Populations Through a 2-Step Diagnostic Test Comprised of Rapid IHC Enrichment Followed by Sensitive Next-Generation Sequencing

Murphy¹, DA; Ely, HA; Shoemaker, R; Boomer, A; Culver, BP; Hoskins, I; Haimes, JD; Walters, RD; Fernandez, D; Stahl, JA; Lee, J; Kim, KM; Lamoureux, J; Christiansen, J

J Cancer 2017 10.7150/jca.18286

The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer

Kim¹, ST; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS

J Cancer 2017 10.7150/jca.19458

The Impact of Cetuximab Plus AKT- or mTOR-Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation

Kim¹, JS; Kim, JE; Kim, K; Lee, J; Park, JO; Lim, HY; Park, YS; Kang, WK; Kim, ST

J Cancer 2017 10.7150/jca.19582

MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines

Kim¹, JE; Kim, KK; Kim, SY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST

Genome Res. 2017 Apr;27(4):524-532. doi: 10.1101/gr.213348.116.

Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma

Liang WS1¹, Hendricks W1, Kiefer J1, Schmidt J2, Sekar S1, Carpten J1, Craig DW1, Adkins J1, Cuyugan L1, Manojlovic Z1, Halperin RF1, Helland A1, Nasser S1, Legendre C1, Hurley LH3, Sivaprakasam K1, Johnson DB4, Crandall H4, Busam KJ5, Zismann V1, Deluca V1, Lee J6, Sekulic A1,2, Ariyan CE5, Sosman J7, Trent J1.

Cancer Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9.

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Drilon A1¹, Siena S2,3, Ou SI4, Patel M5, Ahn MJ6, Lee J6, Bauer TM7, Farago AF8, Wheler JJ9, Liu SV10, Doebele R11, Giannetta L2, Cerea G2, Marrapese G2, Schirru M2, Amatu A2, Bencardino K2, Palmeri L2, Sartore-Bianchi A2, Vanzulli A2,3, Cresta S12, Damian S12, Duca M12, Ardini E13, Li G14, Christiansen J14, Kowalski K14, Johnson AD14, Patel R14, Luo D14, Chow-Maneval E14, Hornby Z14, Multani PS14, Shaw AT8, De Braud FG3,12.

Oncotarget. 2017 Mar 7;8(10):16233-16242. doi: 10.18632/oncotarget.9069.

IKK epsilon and TBK1 expression in gastric cancer

Lee SE1¹, Hong M2, Cho J3, Lee J4, Kim KM3.

Ann Oncol. 2017 Mar 1;28(3):547-554. doi: 10.1093/annonc/mdw669.

Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition

Kim ST1¹, Kim SY1, Klempner SJ2,3, Yoon J4, Kim N4, Ahn S4,5, Bang H5,6, Kim KM5,6, Park W4, Park SH1, Park JO1, Park YS1, Lim HY1, Lee SH1, Park K1,6, Kang WK1, Lee J1.

BMC Cancer. 2017 Mar 23;17(1):211. doi: 10.1186/s12885-017-3196-6.

Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy

Kim ST1¹, Lee J1, Park SH1, Park JO1, Park YS1, Kang WK1, Lim HY2.

Oncotarget. 2017 Feb 21;8(8):13320-13328. doi: 10.18632/oncotarget.14519.

Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability

Cho J1¹, Lee J2, Bang H3, Kim ST2, Park SH2, An JY4, Choi MG4, Lee JH4, Sohn TS4, Bae JM4, Kang WK2, Kim S4, Kim KM3.

Oncotarget. 2017 Feb 28;8(9):15014-15022. doi: 10.18632/oncotarget.14788.

Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion

Kim SY1¹, Ahn T2, Bang H3, Ham JS1, Kim J1, Kim ST1, Jang J1, Shim M1, Kang SY3, Park SH1, Min BH4, Lee H4, Kang WK1, Kim KM3, Park W2,5, Lee J1.

Oncotarget. 2017 Feb 14;8(7):11094-11104. doi: 10.18632/oncotarget.14362.

Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer

Kim JH1¹, Lee SH2, Choi S2, Kim U3, Yeo IS4, Kim SH2, Oh MJ3, Moon H3, Lee J3, Jeong S3, Choi MG5, Lee JH5, Sohn TS5, Bae JM5, Kim S5, Min YW5, Lee H5, Lee JH5, Rhee PL5, Kim JJ5, Lee SJ5, Kim ST5, Lee J5, Park SH5, Park JO5, Park YS5, Lim HY5, Kang WK5, An HJ3, Kim JH4.

J Cancer. 2017 Feb 25;8(5):730-736. doi: 10.7150/jca.17887. eCollection 2017.

An investigation of the role of gene copy number variations in sorafenib sensitivity in metastatic hepatocellular carcinoma patients

Lee JY1¹, Hong M2, Lee J3, Lee S3, Kim KM2, Park C4, Lim HY3.

Cancer Res Treat. 2017 Jan;49(1):44-53. doi: 10.4143/crt.2016.024. Epub 2016 Apr 27.

Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort

Jung M1¹, Lee J2, Kim TM3, Lee DH4, Kang JH5, Oh SY6, Lee SJ7, Shin SJ1.

Oncotarget. 2017 Jan 10;8(2):3237-3245. doi: 10.18632/oncotarget.13700.

The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors

Lim SH1¹, Kim SY1, Kim K2, Jang H1, Ahn S2, Kim KM2, Kim NK3, Park W3, Lee SJ1, Kim ST1, Park SH1, Park JO1, Park YS1, Lee SH1, Lim HY1, Park K1, Kang WK1, Lee J1.

J Cancer. 2016 Feb 5;7(5):484-9. doi: 10.7150/jca.13711. eCollection 2016.

The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs

Kim ST1¹, Ha SY2, Lee S1, Ahn S2, Lee J1, Park SH1, Park JO1, Lim HY1, Kang WK1, Kim KM2, Park YS1.

Clin Genitourin Cancer. 2016 Feb;14(1):76-81. doi: 10.1016/j.clgc.2015.09.008. Epub 2015 Sep 25.

A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma

Kim YS1¹, Lee SI2, Park SH3, Park S3, Hwang IG4, Lee SC5, Sun JM3, Lee J3, Lim HY3.

BMC Cancer. 2016 Feb 18;16:120. doi: 10.1186/s12885-016-2141-4.

The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis

Kim HS1¹,2, Heo JS3, Lee J4, Lee JY5, Lee MY6, Lim SH7, Lee WY8, Kim SH9, Park YA10, Cho YB11, Yun SH12, Kim ST13, Park JO14, Lim HY15, Choi YS16, Kwon WI17, Kim HC18, Park YS19.

Transl Oncol. 2016 Dec;9(6):557-564. doi: 10.1016/j.tranon.2016.09.004. Epub 2016 Nov 22.

Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma

Kim HK1¹, Lee S2, Kim K3, Heo MH1, Lee H1, Cho J1, Kim NK4, Park W5, Lee SJ1, Kim JH6, Jang KT7, Choi SH8, Lee J9.

Invest New Drugs. 2016 Dec;34(6):677-684. Epub 2016 Aug 4.

Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry

Cho J1¹, Ahn S2, Yoo KH1, Kim JH3, Choi SH4, Jang KT5, Lee J6.

Oncologist. 2016 Sep 28. pii: theoncologist.2016-0148.

Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer

Rankin A1¹, Klempner SJ2, Erlich R1, Sun JX1, Grothey A3, Fakih M4, George TJ Jr5, Lee J6, Ross JS7, Stephens PJ1, Miller VA1, Ali SM1, Schrock AB8.

Transl Oncol. 2016 Oct;9(5):466-471. doi: 10.1016/j.tranon.2016.08.009.

Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma

Cho J1¹, Lee J1, Kim J1, Kim ST1, Lee S1, Kim SY1, Ha SY2, Park CK3, Lim HY4.

J Cancer. 2016 Oct 25;7(15):2173-2178. eCollection 2016.

To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients

Lee H1¹, Lee J2, Sohn I3, Park SH2, Park JO2, Park YS2, Kim KM4, Kang WK2, Kim ST2.

Gastroenterology. 2016 Oct;151(4):637-650.e10. doi: 10.1053/j.gastro.2016.06.043. Epub 2016 Jul 1.

ADAR-Mediated RNA Editing Predicts Progression and Prognosis of Gastric Cancer

Chan TH1¹, Qamra A2, Tan KT1, Guo J1, Yang H1, Qi L1, Lin JS1, Ng VH1, Song Y1, Hong H1, Tay ST3, Liu Y4, Lee J5, Rha SY6, Zhu F7, So JB7, Teh BT8, Yeoh KG9, Rozen S10, Tenen DG11, Tan P12, Chen L13.

Support Care Cancer. 2016 Jan;24(1):301-9. doi: 10.1007/s00520-015-2783-9. Epub 2015 Jun 4.

Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects

Hwang IG1¹, Kang JH2, Oh SY3,4, Lee S5, Kim SH5, Song KH6, Son C7, Park MJ8, Kang MH2, Kim HG2, Lee J9, Park YS9, Sun JM9, Kim HJ10, Kim CK10, Yi SY11, Jang JS1, Park K12,13, Kim HJ5.

Cancer Res Treat. 2016 Jan;48(1):153-61. doi: 10.4143/crt.2014.183. Epub 2015 Mar 7.

The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors

Kim M1¹, Lee S2, Lee J2, Park SH2, Park JO2, Park YS2, Kang WK2, Kim ST2.

Oncotarget. 2016 Jan 26;7(4):4024-35. doi: 10.18632/oncotarget.6602.

Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors

Park C1¹, Ha SY1, Kim ST2, Kim HC3, Heo JS3, Park YS2, Lauwers G4, Lee J2, Kim KM1.

Mod Pathol. 2016 Sep;29(9):1095-103. doi: 10.1038/modpathol.2016.96. Epub 2016 May 27.

FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival

Ahn S1¹,2, Lee J3, Hong M4, Kim ST3, Park SH3, Choi MG5, Lee JH5, Sohn TS5, Bae JM5, Kim S5, Jung SH6, Kang WK3, Kim KM1,2.

Oncogene. 2016 Aug 25;35(34):4437-46. doi: 10.1038/onc.2015.514. Epub 2016 Feb 8.

Novel strategy for a bispecific antibody: induction of dual target internalization and degradation

Lee JM1¹, Lee SH2, Hwang JW3, Oh SJ1, Kim B1, Jung S1, Shim SH2, Lin PW4, Lee SB4, Cho MY5, Koh YJ5, Kim SY6, Ahn S7, Lee J6, Kim KM6, Cheong KH5, Choi J2, Kim KA1.

J Clin Oncol. 2016 Aug 10;34(23):2728-35. doi: 10.1200/JCO.2015.65.1901. Epub 2016 Jun 20.

Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial

Pavlakis N1¹, Sjoquist KM2, Martin AJ2, Tsobanis E2, Yip S2, Kang YK2, Bang YJ2, Alcindor T2, O'Callaghan CJ2, Burnell MJ2, Tebbutt NC2, Rha SY2, Lee J2, Cho JY2, Lipton LR2, Wong M2, Strickland A2, Kim JW2, Zalcberg JR2, Simes J2, Goldstein D2.

Clin Cancer Res. 2016 Aug 1;22(15):3831-40. doi: 10.1158/1078-0432.CCR-15-3000. Epub 2016 Mar 1.

Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target

Yakirevich E1¹, Resnick MB2, Mangray S2, Wheeler M2, Jackson CL2, Lombardo KA2, Lee J3, Kim KM4, Gill AJ5, Wang K6, Gowen K6, Sun J6, Miller VA6, Stephens PJ6, Ali SM6, Ross JS7, Safran H8.

Mol Diagn Ther. 2016 Aug;20(4):375-83. doi: 10.1007/s40291-016-0205-4.

A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer

Ahn S1¹,2, Hong M3, Van Vrancken M4, Lyou YJ2, Kim ST5, Park SH5, Kang WK5, Park YS5, Jung SH6, Woo M6, Lee J7, Kim KM8,9.

Oncotarget. 2016 Jul 12;7(28):43492-43503. doi: 10.18632/oncotarget.9523.

MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis

Lee JY1¹, Lee I2, Chang WJ3, Ahn SM4,5, Lim SH1, Kim HS1, Yoo KH1, Jung KS1, Song HN1, Cho JH1, Kim SY1, Kim KM4,5, Lee S1, Kim ST1, Park SH1, Lee J1, Park JO1, Park YS1, Lim HY1, Kang WK1.

J Cancer Res Clin Oncol. 2016 Jun;142(6):1231-7. doi: 10.1007/s00432-016-2143-2. Epub 2016 Mar 16.

Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin)

Kim ST1¹, Ahn S2, Lee J1, Lee SJ1, Park SH1, Park YS1, Lim HY1, Kang WK1, Kim KM2, Park JO3.

Transl Oncol. 2016 Jun;9(3):197-202. doi: 10.1016/j.tranon.2016.03.008. Epub 2016 May 12.

BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells

Kim HK1¹, Kim SY1, Lee SJ1, Kang M1, Kim ST1, Jang J1, Rath O2, Schueler J2, Lee DW3, Park WY4, Kim SJ5, Park SH1, Lee J6.

Transl Cancer Res. 2016 Jun;5(Suppl 1):S25-S30. doi: 10.21037/tcr.2016.05.21.

Moving molecular subtypes to the clinic in gastric cancer

Chao J1¹, Lee J2, Klempner SJ3,4.

Transl Oncol. 2016 Jun;9(3):173-8. doi: 10.1016/j.tranon.2016.01.007. Epub 2016 Apr 22.

Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing

Yoo KH1¹, Kim NK2, Kwon WI3, Lee C2, Kim SY1, Jang J1, Ahn J1, Kang M1, Jang H1, Kim ST1, Ahn S4, Jang KT4, Park YS1, Park WY5, Lee J6, Heo JS7, Park JO8.

J Cancer. 2016 May 25;7(9):1044-8. doi: 10.7150/jca.14815. eCollection 2016.

Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era

Kim ST1¹, Lee SJ1, Park SH1, Park JO1, Lim HY1, Kang WK1, Lee J1, Park YS1.

Medicine (Baltimore). 2016 May;95(19):e3534. doi: 10.1097/MD.0000000000003534.

The Clinicopathologic Features and Treatment of 607 Hindgut Neuroendocrine Tumor (NET) Patients at a Single Institution

Kim ST1¹, Ha SY, Lee J, Hong SN, Chang DK, Kim YH, Park YA, Huh JW, Cho YB, Yun SH, Lee WY, Kim HC, Park YS.

Cancer Res. 2016 May 1;76(9):2573-86. doi: 10.1158/0008-5472.CAN-16-0022.

Stromal-Based Signatures for the Classification of Gastric Cancer

Uhlik MT1¹, Liu J1, Falcon BL1, Iyer S2, Stewart J1, Celikkaya H2, O'Mahony M2, Sevinsky C3, Lowes C3, Douglass L4, Jeffries C1, Bodenmiller D1, Chintharlapalli S1, Fischl A1, Gerald D2, Xue Q2, Lee JY5, Santamaria-Pang A3, Al-Kofahi Y3, Sui Y3, Desai K3, Doman T1, Aggarwal A1, Carter JH4, Pytowski B2, Jaminet SC6, Ginty F3, Nasir A1, Nagy JA6, Dvorak HF6, Benjamin LE7.

Cancer Res Treat. 2016 Apr;48(2):553-60. doi: 10.4143/crt.2015.155. Epub 2015 Aug 10.

A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology

Yi JH1¹, Kang JH2, Hwang IG3, Ahn HK4, Baek HJ5, Lee SI5, Lim DH5, Won YW6, Ji JH7, Kim HS8, Rha SY8, Oh SY9, Lee KE10, Lim T11, Maeng CH12, Kim MJ13, Kim ST13, Lee J13, Park JO13, Park YS13, Lim HY13, Kang WK13, Park SH13.

Oncotarget. 2016 Apr 12;7(15):19610-9. doi: 10.18632/oncotarget.7526.

Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment

Song HN1¹,2, Lee C3,4, Kim ST1, Kim SY1, Kim NK3, Jang J1, Kang M1, Jang H1, Ahn S5, Kim SH5, Park Y6, Cho YB6, Heo JW6, Lee WY6, Park JO1, Lim HY1, Kang WK1, Park YS1, Park WY3,7,4, Lee J1, Kim HC6.

Oncotarget. 2016 Apr 26;7(17):24088-96. doi: 10.18632/oncotarget.8175.

Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer

Kim ST1¹, Lee J1, Lee SJ1, Park SH1, Jung SH2, Park YS1, Lim HY1, Kang WK1, Park JO1.

Oncotarget. 2016 Mar 1;7(9):10547-56. doi: 10.18632/oncotarget.7234.

Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus

Lim SM1¹,2, Park HS3, Kim S4, Kim S4, Ali SM5, Greenbowe JR5, Yang IS4, Kwon NJ6, Lee JL7, Ryu MH7, Ahn JH7, Lee J8, Lee MG3, Kim HS1, Kim H9, Kim HR1, Moon YW1,2, Chung HC1, Kim JH2, Kang YK7, Cho BC1.

Oncotarget. 2016 Feb 9;7(6):6538-51. doi: 10.18632/oncotarget.3731.

Integrated genomic analyses identify frequent gene fusion events and VHL inactivation in gastrointestinal stromal tumors

Kang G1¹,2, Yun H1,3, Sun CH3, Park I3, Lee S3, Kwon J3, Do I1,4,5, Hong ME1,5,6, Van Vrancken M1, Lee J7, Park JO7, Cho J8, Kim KM1,5, Sohn TS9.

Tumori. 2016 Jan-Feb;102(1):114-21. doi: 10.5301/tj.5000439. Epub 2015 Oct 7.

Clinical significance of mucinous rectal adenocarcinoma following preoperative chemoradiotherapy and curative surgery

Kim TG1¹, Park W2, Choi DH2, Park HC2, Kim SH3, Cho YB4, Yun SH4, Kim HC4, Lee WY4, Lee J5, Park JO5, Park YS5, Lim HY5, Kang WK5, Chun HK6.

PLoS One. 2015 Sep 11;10(9):e0137657. doi: 10.1371/journal.pone.0137657. eCollection 2015.

Copy Number Gains at 8q24 and 20q11-q13 in Gastric Cancer Are More Common in Intestinal-Type than Diffuse-Type

Jin DH1¹, Park SE1, Lee J2, Kim KM3, Kim S4, Kim DH1, Park J1.

Oncotarget. 2015 Sep 15;6(27):24320-32.

Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening

Lee J1¹, Kim HC2, Hong JY3, Wang K4, Kim SY1, Jang J1, Kim ST1, Park JO1, Lim HY1, Kang WK1, Park YS1, Lee J1, Lee WY2, Park YA2, Huh JW2, Yun SH2, Do IG5, Kim SH5, Balasubramanian S4, Stephens PJ4, Ross JS4,6, Li GG7, Hornby Z7, Ali SM4, Miller VA4, Kim KM5,8, Ou SH9.

Oncotarget. 2015 Sep 29;6(29):28211-22. doi: 10.18632/oncotarget.4721.

Gastrointestinal malignancies harbor actionable MET exon 14 deletions

Lee J1¹,2, Ou SH3, Lee JM4, Kim HC5, Hong M6, Kim SY1, Jang J1, Ahn S6, Kang SY6, Lee S1, Kim ST1, Kim B4, Choi J4, Kim KA4, Lee J1, Park C1,6, Park SH1, Park JO1,2, Lim HY1, Kang WK1, Park K1,2, Park YS1, Kim KM2,6.

Oncotarget. 2015 Sep 22;6(28):25619-30. doi: 10.18632/oncotarget.4627.

Patient-derived cell models as preclinical tools for genome-directed targeted therapy

Lee JY1¹, Kim SY1, Park C1, Kim NK2, Jang J1, Park K2, Yi JH3, Hong M4,5, Ahn T2, Rath O6, Schueler J6, Kim ST1, Do IG5, Lee S1, Park SH1, Ji YI7, Kim D7, Park JO1,4, Park YS1, Kang WK1, Kim KM4,5, Park WY2,7, Lim HY1, Lee J1,4.

Mol Ther. 2015 Sep;23(9):1532-40. doi: 10.1038/mt.2015.109. Epub 2015 Jun 15.

Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer

Park SH1¹, Breitbach CJ2, Lee J1, Park JO1, Lim HY1, Kang WK1, Moon A2,3, Mun JH4, Sommermann EM4, Maruri Avidal L4, Patt R5, Pelusio A2, Burke J2, Hwang TH4,6, Kirn D2, Park YS1.

World J Gastroenterol. 2015 Apr 14;21(14):4268-74. doi: 10.3748/wjg.v21.i14.4268.

Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma

Lee MY1¹, Jung KS1, Kim HS1, Lee JY1, Lim SH1, Kim M1, Jung HA1, Kim SM1, Sun JM1, Ahn MJ1, Lee J1, Park SH1, Yi SY1, Hwang IG1, Lee SC1, Ahn HK1, Lim DH1, Lee SI1, Park KW1.

BMC Cancer. 2015 Mar 19;15:154. doi: 10.1186/s12885-015-1160-x.

Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series

Yoo KH1¹, Kim HS2, Lee SJ3, Park SH4, Kim SJ5, Kim SH6, La Choi Y7, Shin KH8, Cho YJ9, Lee J10, Rha SY11.

Oncotarget. 2015 Dec 22;6(41):43731-42. doi: 10.18632/oncotarget.6192.

Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer

Lee JY1¹, Park K2, Lim SH1, Kim HS1, Yoo KH1, Jung KS1, Song HN1, Hong M3, Do IG3, Ahn T2, Lee SK4, Bae SY4, Kim SW4, Lee JE4, Nam SJ4, Kim DH5, Jung HH6, Kim JY1, Ahn JS1, Im YH1, Park YH1.

Br J Cancer. 2015 Nov 17;113(10):1421-6. doi: 10.1038/bjc.2015.371. Epub 2015 Oct 27.

A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer

Lim SH1¹, Kim TW2, Hong YS2, Han SW3, Lee KH3, Kang HJ4, Hwang IG5, Lee JY1, Kim HS1, Kim ST1, Lee J1, Park JO1, Park SH1, Park YS1, Lim HY1, Jung SH6,7, Kang WK1.

Gut. 2015 Nov;64(11):1721-31. doi: 10.1136/gutjnl-2014-308252. Epub 2014 Nov 10.

Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas

Lin SJ1¹, Gagnon-Bartsch JA2, Tan IB3, Earle S4, Ruff L4, Pettinger K4, Ylstra B5, van Grieken N5, Rha SY6, Chung HC6, Lee JS7, Cheong JH8, Noh SH8, Aoyama T9, Miyagi Y10, Tsuburaya A11, Yoshikawa T9, Ajani JA12, Boussioutas A13, Yeoh KG14, Yong WP15, So J16, Lee J17, Kang WK17, Kim S18, Kameda Y19, Arai T20, Zur Hausen A21, Speed TP22, Grabsch HI23, Tan P24.

Oncotarget. 2015 Nov 24;6(37):40360-9. doi: 10.18632/oncotarget.5465.

Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients

Kim ST1¹, Lee WS2, Lanman RB3, Mortimer S3, Zill OA3, Kim KM4,5, Jang KT5, Kim SH5, Park SH1, Park JO1,4, Park YS1, Lim HY1, Eltoukhy H3, Kang WK1, Lee WY6, Kim HC6, Park K1,4, Lee J1,4, Talasaz A3.

Oncotarget. 2015 Nov 24;6(37):40026-35. doi: 10.18632/oncotarget.5432.

PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA

Kim ST1¹, Lira M2, Deng S2, Lee S1, Park YS1, Lim HY1, Kang WK1, Mao M3, Heo JS4, Kwon W4, Jang KT5, Lee J1,6, Park JO1,6.

Oncologist. 2015 Nov;20(11):1312-9. doi: 10.1634/theoncologist.2015-0161. Epub 2015 Sep 30.

Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06)

Lee SJ1¹, Kim TM2, Kim YJ3, Jang KT4, Lee HJ5, Lee SN6, Ahn MS7, Hwang IG8, Lee S9, Lee MH10, Lee J11.

Oncotarget. 2015 Nov 17;6(36):39028-35. doi: 10.18632/oncotarget.5494.

NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line

Lee SJ1¹, Li GG2, Kim ST1, Hong ME3, Jang J1, Yoon N3, Ahn SM3, Murphy D2, Christiansen J2, Wei G2, Hornby Z2, Lee DW4, Park JO1,5, Park YS1, Lim HY1, Hong SN6, Kim SH3, Kang WK1, Park K1, Park WY7, Kim KM3,5, Lee J1.

BMC Cancer. 2015 Oct 14;15:693. doi: 10.1186/s12885-015-1716-9.

Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study

Lee SJ1¹, Kim S2, Kim M3, Lee J4, Park YH5, Im YH6, Park SH7.

Int J Biol Markers. 2015 Nov 11;30(4):e382-6. doi: 10.5301/jbm.5000151.

Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer

Lee SJ1¹, Lee J1, Kim ST1, Park SH1, Park JO1, Park YS1, Lim HY1, Kang WK1.

PLoS One. 2015 Oct 16;10(10):e0140712. doi: 10.1371/journal.pone.0140712. eCollection 2015.

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA

Lanman RB1¹, Mortimer SA2, Zill OA2, Sebisanovic D2, Lopez R2, Blau S3, Collisson EA4, Divers SG5, Hoon DS6, Kopetz ES7, Lee J8, Nikolinakos PG9, Baca AM1, Kermani BG2, Eltoukhy H10, Talasaz A11.

Oncotarget. 2015 Oct 20;6(32):33358-68. doi: 10.18632/oncotarget.5188.

The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis

Kim ST1¹, Lee J1, Hong M2,3, Park K4,5, Park JO1, Ahn T3,4, Park SH1, Park YS1, Lim HY1, Sun JM1, Ahn JS1, Ahn MJ1, Kim HC6, Sohn TS6, Choi DI7, Cho JH8, Heo JS6, Kwon W6, Uhm SW9, Lee H10, Min BH10, Hong SN10, Kim DH5,11, Jung SH12, Park W4,5, Kim KM2,3, Kang WK1, Park K1,2.

J Clin Oncol. 2015 Oct 1;33(28):3130-6. doi: 10.1200/JCO.2014.58.3930. Epub 2015 Jan 5.

Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses

Park SH1¹, Sohn TS1, Lee J1, Lim DH1, Hong ME1, Kim KM1, Sohn I1, Jung SH1, Choi MG1, Lee JH1, Bae JM1, Kim S1, Kim ST1, Park JO1, Park YS1, Lim HY1, Kang WK2.

Cancer Res Treat. 2015 Oct;47(4):738-46. doi: 10.4143/crt.2014.224. Epub 2015 Feb 16.

Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopatholoqical Analysis of 72 Cases in a Single Institute

Shin Y1¹, Ha SY1, Hyeon J1, Lee B1, Lee J2, Jang KT1, Kim KM1, Park YS2, Park CK1.

BMC Cancer. 2015 Oct 20;15:747. doi: 10.1186/s12885-015-1759-y.

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan

Kim ST¹, Ahn TJ, Lee E, Do IG, Lee SJ, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim SH, Lee J, Kim HC

Radiother Oncol. 2015 Oct;117(1):171-7. doi: 10.1016/j.radonc.2015.08.009. Epub 2015 Aug 20.

Effects of adjuvant radiotherapy on completely resected gastric cancer: A radiation oncologist's view of the ARTIST randomized phase III trial

Yu JI1¹, Lim do H2, Ahn YC1, Lee J3, Kang WK3, Park SH3, Park JO3, Park YS3, Lim HY3, Kim ST3, Kim S4, Sohn TS4, Choi MG4, Bae JM4, Nam H5.

Oncotarget. 2015 Aug 21;6(24):20190-203.

Overexpression of MAPK15 in gastric cancer is associated with copy number gain and contributes to the stability of c-Jun

Jin DH1¹, Lee J2, Kim KM3, Kim S4, Kim DH1, Park J1.

Transl Oncol. 2015 Aug;8(4):288-94. doi: 10.1016/j.tranon.2015.06.001.

Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer

Kim ST1¹, Jang HL2, Lee J1, Park SH1, Park YS1, Lim HY1, Choi MG3, Bae JM3, Sohn TS3, Noh JH3, Kim S3, Kim KM4, Kang WK1, Park JO5.

BMC Cancer. 2015 Jul 21;15:530. doi: 10.1186/s12885-015-1552-y.

Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer

Kim ST1¹, Jang KT2, Lee SJ3, Jang HL4, Lee J5, Park SH6, Park YS7, Lim HY8, Kang WK9, Park JO10.

Support Care Cancer. 2015 Jun;23(6):1769-77. doi: 10.1007/s00520-014-2507-6. Epub 2014 Dec 3.

A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients

Kim JE1¹, Hong YS, Lee JL, Kim KP, Park SJ, Sym SJ, Shin DB, Lee J, Park YS, Ahn JS, Kim TW.

Clin Transl Oncol. 2015 Jun;17(6):462-8. doi: 10.1007/s12094-014-1258-7. Epub 2014 Dec 2.

The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer

Kim ST1¹, Do IG, Lee J, Sohn I, Kim KM, Kang WK.

Nat Med. 2015 May;21(5):449-56. doi: 10.1038/nm.3850. Epub 2015 Apr 20.

Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes

Cristescu R1¹, Lee J2, Nebozhyn M1, Kim KM3, Ting JC4, Wong SS4, Liu J4, Yue YG4, Wang J4, Yu K4, Ye XS4, Do IG3, Liu S5, Gong L5, Fu J6, Jin JG6, Choi MG7, Sohn TS7, Lee JH7, Bae JM7, Kim ST2, Park SH2, Sohn I8, Jung SH8, Tan P9, Chen R1, Hardwick J1, Kang WK2, Ayers M1, Hongyue D1, Reinhard C4, Loboda A1, Kim S7, Aggarwal A4.

Int J Cancer. 2015 Apr 1;136(7):1629-35. doi: 10.1002/ijc.29159. Epub 2014 Sep 4.

HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: A distinct subset of patients for dual inhibition therapy

Ha SY1¹, Lee J, Jang J, Hong JY, Do IG, Park SH, Park JO, Choi MG, Sohn TS, Bae JM, Kim S, Kim M, Kim S, Park CK, Kang WK, Kim KM.

Ann Oncol. 2015 Apr;26(4):762-8. doi: 10.1093/annonc/mdu584. Epub 2014 Dec 23.

A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer

Lim SH1¹, Lee JY1, Lee MY1, Kim HS1, Lee J1, Sun JM1, Ahn JS1, Um SW2, Kim H2, Kim BS3, Kim ST4, Na DL5, Sun JY6, Jung SH7, Park K1, Kwon OJ2, Lee JI3, Ahn MJ8.

World J Gastroenterol. 2015 Apr 14;21(14):4268-74. doi: 10.3748/wjg.v21.i14.4268.

Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma

Lee MY1¹, Jung KS1, Kim HS1, Lee JY1, Lim SH1, Kim M1, Jung HA1, Kim SM1, Sun JM1, Ahn MJ1, Lee J1, Park SH1, Yi SY1, Hwang IG1, Lee SC1, Ahn HK1, Lim do H1, Lee SI1, Park KW1.

Sci Rep. 2015 Mar 19;5:9289. doi: 10.1038/srep09289.

The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer

Lee JY1¹, Hong M2, Kim ST1, Park SH1, Kang WK1, Kim KM2, Lee J1.

Transl Oncol. 2015 Feb;8(1):40-6. doi: 10.1016/j.tranon.2014.12.003.

Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer

Kim ST1¹, Jang KT2, Lee J1, Jang HM3, Choi HJ4, Jang HL1, Park SH1, Park YS1, Lim HY1, Kang WK1, Park JO5.

Cancer Res Treat. 2015 Jan;47(1):72-7. doi: 10.4143/crt.2013.172. Epub 2014 Aug 21.

Changes in the Mean Corpuscular Volume after Capecitabine Treatment are Associated with Clinical Response and Survival in Patients with Advanced Gastric Cancer

Jung HA1¹, Kim HJ2, Maeng CH3, Park SH1, Lee J1, Park JO1, Park YS1, Lim HY1, Kang WK1.

BRITISH JOURNAL OF CANCER, JUL 29 2014, 111(3), 497-505, DOI: 10.1038/bjc.2014.283

Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90 alpha in human colorectal cancer

Lee SJ. Lee I¹, Lee J, Park C, Kang WK

Med Oncol. 2014 Jul;31(7):23. doi: 10.1007/s12032-014-0023-7. Epub 2014 Jun 10.

Prognostic and predictive value of metabolic tumor volume on F-18-FDG PET/CT in advanced biliary tract cancer treated with gemcitabine/oxaliplatin with or without erlotinib

Choi MK11¹, Choi JY, Lee J, Heo JS, Choi SH, Choi DW, Lee KT, Lee JK, Lee KH, Park JO, Park YS, Lim HY.

World J Gastroenterol. 2014 May 28;20(20):6133-45. doi: 10.3748/wjg.v20.i20.6133.

Pulmonary metastasectomy for colorectal cancer: How many nodules, how many times

Kim HK1¹, Cho JH1, Lee HY1, Lee J1, Kim J1.

J Thorac Oncol. 2014 Apr;9(4):506-11. doi: 10.1097/JTO.0000000000000095.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non-Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either Exon 19 or 21

Lim SH1¹, Lee JY, Sun JM, Ahn JS, Park K, Ahn MJ.

Ann Surg Oncol. 2014 Apr;21(4):1099-106. doi: 10.1245/s10434-013-3339-1. Epub 2013 Dec 4.

CD151 Overexpression is Associated with Poor Prognosis in Patients with pT3 Gastric Cancer

Ha SY1¹, Do IG, Lee J, Park SH, Park JO, Kang WK, Choi MG, Lee JH, Bae JM, Kim S, Kim KM, Sohn TS.

Int J Colorectal Dis. 2014 Feb;29(2):193-200. doi: 10.1007/s00384-013-1797-3. Epub 2013 Dec 10.

Factors associated with lateral pelvic recurrence after curative resection following neoadjuvant chemoradiotherapy in rectal cancer patients

Kim TG1¹, Park W, Choi DH, Park HC, Kim SH, Cho YB, Yun SH, Kim HC, Lee WY, Lee J, Park JO, Park YS, Lim HY, Kang WK, Chun HK.

Exp Mol Pathol. 2014 Dec;97(3):440-4. doi: 10.1016/j.yexmp.2014.09.013. Epub 2014 Oct 1.

The analysis of mutations and exon deletions at TSC2 gene in angiomyolipomas associated with tuberous sclerosis complex

Yang HM1¹, Choi HJ1, Hong DP1, Joo SY2, Lee NE2, Song JY3, Choi YL4, Lee J5, Choi D6, Kim B7, Park HJ8, Park JB9, Kim SJ10.

Sci Rep.?2014 Dec 23;4:7592. doi: 10.1038/srep07592.

Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer

Yi JH1¹,?Do IG2,?Jang J3,?Kim ST3,?Kim KM4,?Park SH3,?Park JO3,?Park YS3,?Lim HY3,?Kang WK3,?Lee J3.

Eur J Cancer. 2014 Nov;50(16):2822-30. doi: 10.1016/j.ejca.2014.08.005. Epub 2014 Sep 15.

Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: A double-blind randomised phase 3 study

Kim ST1¹, Kang JH2, Lee J1, Park SH1, Park JO1, Park YS1, Lim HY1, Hwang IG3, Lee SC4, Park KW5, Lee HR6, Kang WK7.

PLoS One.?2014 Nov 5;9(11):e111693. doi: 10.1371/journal.pone.0111693. eCollection 2014.

High-Throughput Sequencing and Copy Number Variation Detection Using Formalin Fixed Embedded Tissue in Metastatic Gastric Cancer

Kim S1¹,?Lee J2,?Hong ME3,?Do IG3,?Kang SY1,?Ha SY1,?Kim ST2,?Park SH2,?Kang WK2,?Choi MG4,?Lee JH4,?Sohn TS4,?Bae JM4,?Kim S4,?Kim DH5,?Kim KM3.

Anticancer Res. 2014 Nov;34(11):6585-91.

Adjuvant Chemoradiation with 5-Fluorouracil/Leucovorin versus S-1 in Gastric Cancer Patients Following D2 Lymph Node Dissection Surgery: A Feasibility Study

Lee SJ1¹, Sohn TS2, Lee J1, Park SH1, Park JO1, Lim DH3, Park YS1, Lim HY1, Choi MG4, Lee JH4, Bae JM4, Kim S4, Kang WK5.

Nat Commun. 2014 Nov 19;5:5477. doi: 10.1038/ncomms6477.

Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing

Wong SS1¹, Kim KM2, Ting JC1, Yu K1, Fu J3, Liu S4, Cristescu R5, Nebozhyn M5, Gong L4, Yue YG1, Wang J1, Ronghua C5, Loboda A5, Hardwick J5, Liu X5, Dai H5, Jin JG3, Ye XS1, Kang SY2, Do IG2, Park JO6, Sohn TS7, Reinhard C1, Lee J6, Kim S7, Aggarwal A1.

Mol Cancer Ther. 2014 Nov;13(11):2527-36. doi: 10.1158/1535-7163.MCT-14-0255. Epub 2014 Sep 23.

Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification

Kim ST1¹, Jang HL2, Lee SJ1, Lee J1, Choi YL3, Kim KM3, Cho J4, Park SH1, Park YS1, Lim HY1, Yashiro M5, Kang WK1, Park JO6.

BMC Cancer. 2014 Nov 26;14:883. doi: 10.1186/1471-2407-14-883.

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial

Kim ST¹, Hong YS, Lim HY, Lee J, Kim TW, Kim KP, Kim SY, Baek JY, Kim JH, Lee KW, Chung IJ, Cho SH, Lee KH, Shin SJ, Kang HJ, Shin DB, Lee JW, Jo SJ, Park YS1.

Cancer Chemother Pharmacol. 2014 Jan;73(1):125-30. doi: 10.1007/s00280-013-2328-1. Epub 2013 Oct 27.

Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients

Hong JY1¹, Nam EM, Lee J, Park JO, Lee SC, Song SY, Choi SH, Heo JS, Park SH, Lim HY, Kang WK, Park YS.

Histol Histopathol. 2014 Jan;29(1):127-38. Epub 2013 Jul 15.

High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma

Lee SE1¹, Kim YJ2, Kwon MJ3, Choi DI4, Lee J5, Cho J1, Seo SW6, Kim SJ7, Shin YK8, Choi YL9.

Sci Rep. 2014 Jan 10;4:3623. doi: 10.1038/srep03628.

Aberrant CDK4 Amplification in Refractory Rhabdomyosarcoma as Identified by Genomic Profiling

Park S1¹, Lee J1, Do IG2, Jang J2, Rho K3, Ahn S3, Maruja L4, Kim SJ5, Kim KM2, Mao M4, Oh E6, Kim YJ6, Kim J7, Choi YL7.

Cancer?Genomics Proteomics.?2014 Sep-Oct;11(5):259-66.

Transcriptome Analysis of CD133-positive Stem Cells and Prognostic Value of Survivin in Colorectal Cancer

Kim ST1¹,?Sohn I2,?DO IG3,?Jang J4,?Kim SH3,?Jung IH5,?Park JO1,?Park YS1,?Talasaz A6,?Lee J1,?Kim HC7.

PLoS One.?2014 Aug 4;9(8):e103551. doi: 10.1371/journal.pone.0103551. eCollection 2014.

Activated cMET and IGF1R-Driven PI3K Signaling Predicts Poor Survival in Colorectal Cancers Independent of KRAS Mutational Status

Lee J1¹,?Jain A2,?Kim P2,?Lee T2,?Kuller A2,?Princen F2,?In-GuDo3,?Kim SH3,?Park JO1,?Park YS1,?Singh S2,?Kim HC4.

Cancer. 2014 Jul 1;120(13):2016-24. doi: 10.1002/cncr.28635. Epub 2014 Mar 26.

A Randomized, Open-Label Clinical Trial of Tasisulam Sodium Versus Paclitaxel as Second-Line Treatment in Patients With Metastatic Melanoma

Hamid O1¹, Ilaria R Jr, Garbe C, Wolter P, Maio M, Hutson TE, Arance A, Lorigan P, Lee J, Hauschild A, Mohr P, Hahka-Kemppinen M, Kaiser C, Turner PK, Conti I, Grob JJ.

Clin Genet.?2014 Jul;86(1):37-43. doi: 10.1111/cge.12408. Epub 2014 May 10.

Innovative personalized medicine in gastric cancer: time to move forward

Lee J1¹,?Kim KM,?Kang WK,?Ou SH.

Invest New Drugs.?2014 Jun;32(3):535-41. doi: 10.1007/s10637-014-0065-x. Epub 2014 Jan 28.

Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab

Lee J1¹,?Hong YS,?Hong JY,?Han SW,?Kim TW,?Kang HJ,?Kim TY,?Kim KP,?Kim SH,?Do IG,?Kim KM,?Sohn I,?Park SH,?Park JO,?Lim HY,?Cho YB,?Lee WY,?Yun SH,Kim HC,?Park YS,?Kang WK.

Invest New Drugs.?2014 Jun;32(3):561-8. doi: 10.1007/s10637-014-0075-8. Epub 2014 Feb 27.

A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer

Lee J1¹,?Shin SJ,?Chung IJ,?Kim TW,?Chun HG,?Shin DB,?Kim YH,?Song HS,?Han SW,?Kim JG,?Kim SY,?Choi YJ,?Chung HC.

Cancer Chemother Pharmacol.?2014 May;73(5):1063-70. doi: 10.1007/s00280-014-2442-8. Epub 2014 Mar 25.

Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs

Lee JY1¹,?Lim SH,?Kim M,?Kim S,?Jung HA,?Chang WJ,?Choi MK,?Hong JY,?Lee SJ,?Sun JM,?Ahn JS,?Park K,?Ahn MJ.

Invest New Drugs. 2014 Apr;32(2):369-76. doi: 10.1007/s10637-013-0059-0. Epub 2014 Jan 16.

A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis

Jo JC1¹, Hong YS, Kim KP, Lee JL, Lee J, Park YS, Kim SY, Ryu JS, Lee JS, Kim TW.

PLoS One. 2014 Mar 5;9(3):e90133. doi: 10.1371/journal.pone.0090133. eCollection 2014.

Nanostring-Based Multigene Assay to Predict Recurrence for Gastric Cancer Patients after Surgery

Lee J1¹, Sohn I2, Do IG3, Kim KM4, Park SH1, Park JO1, Park YS1, Lim HY1, Sohn TS5, Bae JM5, Choi MG5, Lim do H6, Min BH7, Lee JH7, Rhee PL7, Kim JJ7, Choi DI8, Tan IB9, Das K10, Tan P11, Jung SH2, Kang WK1, Kim S5.

Sci Rep. 2014 Jan 10;4:3623. doi: 10.1038/srep03623.

Aberrant CDK4 Amplification in Refractory Rhabdomyosarcoma as Identified by Genomic Profiling

Park S1¹, Lee J1, Do IG2, Jang J2, Rho K3, Ahn S3, Maruja L4, Kim SJ5, Kim KM2, Mao M4, Oh E6, Kim YJ6, Kim J7, Choi YL2.

BMC Med Genomics.?2014 Jan 9;7:2. doi: 10.1186/1755-8794-7-2.

Whole-genome sequencing of matched primary and metastatic hepatocellular carcinomas

Ouyang L¹,?Lee J,?Park CK,?Mao M,?Shi Y,?Gong Z,?Zheng H,?Li Y,?Zhao Y,?Wang G,?Fu H,?Kim J1,?Lim HY.

Cancer Res Treat.?2013 Dec;45(4):343-8. doi: 10.4143/crt.2013.45.4.343. Epub 2013 Dec 31.

Tumor Lysis Syndrome in a Solid Tumor: A Case Report of a Patient with Invasive Thymoma

Lee JY1¹,?Lim SH1,?Lee JY1,?Kim JH1,?Choi KH1,?Park K1,?Sun JM1,?Ahn JS1,?Ahn MJ1.

Invest New Drugs. 2013 Dec;31(6):1602-8. doi: 10.1007/s10637-013-0028-7. Epub 2013 Sep 14.

Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide

Yoo C1¹, Lee J, Rha SY, Park KH, Kim TM, Kim YJ, Lee HJ, Lee KH, Ahn JH.

Mod Pathol.?2013 Dec;26(12):1632-41. doi: 10.1038/modpathol.2013.108. Epub 2013 Jun 28.

MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas

Ha SY1¹,?Lee J,?Kang SY,?Do IG,?Ahn S,?Park JO,?Kang WK,?Choi MG,?Sohn TS,?Bae JM,?Kim S,?Kim M,?Kim S,?Park CK,?Ignatius Ou SH,?Kim KM.

Target Oncol.?2013 Dec;8(4):271-80. doi: 10.1007/s11523-013-0253-1. Epub 2013 Feb 1.

Gastric cancer (GC) patients with hedgehog pathway activation: PTCH1 and GLI2 as independent prognostic factors

Lee SJ1¹,?Do IG,?Lee J,?Kim KM,?Jang J,?Sohn I,?Kang WK.

Invest New Drugs. 2013 Dec;31(6):1580-6. doi: 10.1007/s10637-013-0022-0. Epub 2013 Sep 7.

Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients

Lee SJ1¹, Lee J, Lee J, Park SH, Park JO, Park YS, Lim HY, Kim KM, Do IG, Jung SH, Yim DS, Kang WK.

Cancer Res Treat.?2013 Dec;45(4):285-94. doi: 10.4143/crt.2013.45.4.285. Epub 2013 Dec 31.

Nomogram to Predict Treatment Outcome of Fluoropyrimidine/Platinum-Based Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma

Jung HA1¹,?Adenis A2,?Lee J1,?Park SH1,?Maeng CH1,?Park S1,?Ahn HK1,?Shim YM3,?Penel N2,?Im YH1.

Br J Cancer. 2013 Sep 17;109(6):1414-9. doi: 10.1038/bjc.2013.470. Epub 2013 Aug 29.

Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours

Ahn HK1¹, Choi JY, Kim KM, Kim H, Choi SH, Park SH, Park JO, Lim HY, Kang WK, Lee J, Park YS.

Korean J Pathol.?2013 Aug;47(4):348-54. doi: 10.4132/KoreanJPathol.2013.47.4.348. Epub 2013 Aug 26.

Comparison of Three BRAF Mutation Tests in Formalin-Fixed Paraffin Embedded Clinical Samples

Ahn S1¹,?Lee J,?Sung JY,?Kang SY,?Ha SY,?Jang KT,?Choi YL,?Kim JS,?Oh YL,?Kim KM.

Melanoma?Res.?2013 Aug;23(4):336-9. doi: 10.1097/CMR.0b013e3283632ca7.

Generalized lymphadenopathy mimicking malignant lymph node metastases after interferon-alpha 2b therapy for melanoma

Yune S1¹,?Jang KT,?Jung SM,?Kim JH,?Lee J.

Discov Med.?2013 Aug;16(86):7-14.

Towards the Goal of Personalized Medicine in Gastric Cancer - Time to Move Beyond HER2 Inhibition. Part II: Targeting Gene Mutations and Gene Amplifications and the Angiogenesis Pathway

Lee J1¹,?Ou SH.

PLoS One. 2013 Jul 29;8(7):e69752. doi: 10.1371/journal.pone.0069752. Print 2013.

Genetic Aberrations in Imatinib-Resistant Dermatofibrosarcoma Protuberans Revealed by Whole Genome Sequencing

Hong JY1¹, Liu X, Mao M, Li M, Choi DI, Kang SW, Lee J, La Choi Y.

Discov Med.?2013 Jun;15(85):333-41.

Towards the Goal of Personalized Medicine in Gastric Cancer - Time to Move Beyond HER2 Inhibition. Part I: Targeting Receptor Tyrosine Kinase Gene Amplification

Lee J1¹,?Ou SH.

Anal Quant Cytopathol Histpathol.?2013 Jun;35(3):146-51.

A Comparative Study of Telomerase Activity and Cytologic Diagnosis in Malignant Ascites

Park ES1¹,?Lee J2,?Kang SY3,?Lee EJ1,?Lee MH4,?Yoon N3,?Oh YL3,?Kim KM3.

Cancer.?2013 May 1;119(9):1627-35. doi: 10.1002/cncr.27967. Epub 2013 Feb 7.

Identification of ROS1 Rearrangement in Gastric Adenocarcinoma

Lee J1¹,?Lee SE,?Kang SY,?Do IG,?Lee S,?Ha SY,?Cho J,?Kang WK,?Jang J,?Ou SH,?Kim KM.

Melanoma?Res.?2013 Apr;23(2):147-51. doi: 10.1097/CMR.0b013e32835efd8d.

Effect of paclitaxel/carboplatin salvage chemotherapy in noncutaneous versus cutaneous metastatic melanoma

Chang W1¹,?Lee SJ,?Park S,?Choi MK,?Hong JY,?Kim YS,?Maeng CH,?Jung HA,?Kim S,?Lee J.

Invest New Drugs.?2013 Feb;31(1):183-91. doi: 10.1007/s10637-012-9853-3. Epub 2012 Jul 11.

Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy

Hong YS1¹,?Lee J,?Kim KP,?Lee JL,?Park YS,?Park JO,?Park SH,?Kim SY,?Baek JY,?Kim JH,?Lee KW,?Kim TY,?Kim TW.

PLoS One. 2013;8(1):e54644. doi: 10.1371/journal.pone.0054644. Epub 2013 Jan 25.

A Novel Proteomics-Based Clinical Diagnostics Technology Identifies Heterogeneity in Activated Signaling Pathways in Gastric Cancers

Lee J1¹, Kim S, Kim P, Liu X, Lee T, Kim KM, Do IG, Park JO, Park SH, Jang J, Hoe N, Harvie G, Kuller A, Jain A, Meyer G, Leesman G, Park YS, Choi MG, Sohn TS, Bae JM, Lim HY, Singh S, Kang WK.

BMC?Cancer.?2012 Dec 12;12:594. doi: 10.1186/1471-2407-12-594.

Unique perception of clinical trials by Korean cancer patients

Lee SJ1¹,?Park LC,?Lee J,?Kim S,?Choi MK,?Hong JY,?Park S,?Maeng CH,?Chang W,?Kim YS,?Park SH,?Park JO,?Lim HY,?Kang WK,?Park YS.

BMC Cancer. 2012 Dec 13;12:596. doi: 10.1186/1471-2407-12-596.

Statins and the risk of gastric cancer in diabetes patients

Lee J1¹, Lee SH, Hur KY, Woo SY, Kim SW, Kang WK.

Invest New Drugs.?2012 Oct;30(5):2008-14. doi: 10.1007/s10637-011-9763-9. Epub 2011 Nov 9.

Nilotinib in patients with metastatic melanoma harboring KIT gene aberration

Cho JH1¹,?Kim KM,?Kwon M,?Kim JH,?Lee J.

PLoS One.?2012;7(8):e41655. doi: 10.1371/journal.pone.0041655. Epub 2012 Aug 3.

High-Throughput Genotyping in Metastatic Esophageal Squamous Cell Carcinoma Identifies Phosphoinositide-3-Kinase and BRAF Mutations

Maeng CH1¹,?Lee J,?van Hummelen P,?Park SH,?Palescandolo E,?Jang J,?Park HY,?Kang SY,?MacConaill L,?Kim KM,?Shim YM.

Pathology.?2012 Aug;44(5):460-4. doi: 10.1097/PAT.0b013e3283559c45.

Multiplex mutation screening by mass spectrometry in gastrointestinal stromal tumours

Kang G1¹,?Lee J,?Jang KT,?Beadling C,?Corless CL,?Heinrich MC,?Park JO,?Kang WK,?Park CK,?Kim KM.

PLoS One.?2012;7(6):e38892. doi: 10.1371/journal.pone.0038892. Epub 2012 Jun 18.

High-Throughput Mutation Profiling Identifies Frequent Somatic Mutations in Advanced Gastric Adenocarcinoma

Lee J1¹,?van Hummelen P,?Go C,?Palescandolo E,?Jang J,?Park HY,?Kang SY,?Park JO,?Kang WK,?MacConaill L,?Kim KM.

Br J?Cancer.?2012 Apr 24;106(9):1469-74. doi: 10.1038/bjc.2012.100. Epub 2012 Mar 29.

Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum

Yi JH1¹,?Lee J,?Lee J,?Park SH,?Park JO,?Yim DS,?Park YS,?Lim HY,?Kang WK.

PLoS One.?2012;7(4):e34456. doi: 10.1371/journal.pone.0034456. Epub 2012 Apr 2.

Metastasis of Neuroendocrine Tumors Are Characterized by Increased Cell Proliferation and Reduced Expression of the ATM Gene

Lee J1¹,?Sung CO,?Lee EJ,?Do IG,?Kim HC,?Yoon SH,?Lee WY,?Chun HK,?Kim KM,?Park YS.

Hum Genet.?2012 Mar;131(3):365-72. doi: 10.1007/s00439-011-1080-z. Epub 2011 Aug 25.

The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations

Ahn MJ1¹,?Won HH,?Lee J,?Lee ST,?Sun JM,?Park YH,?Ahn JS,?Kwon OJ,?Kim H,?Shim YM,?Kim J,?Kim K,?Kim YH,?Park JY,?Kim JW,?Park K.

Cancer Chemother Pharmacol. 2012 Mar;69(3):635-42. doi: 10.1007/s00280-011-1742-5. Epub 2011 Sep 30.

Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma

Lee EM1¹, Rha SY, Lee J, Park KH, Ahn JH.

Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study

Nephrol Dial Transplant. 2012 Jan;27(1):218-25. doi: 10.1093/ndt/gfr267. Epub 2011 May 28.

Uremia induces functional incompetence of bone marrow-derived stromal cells

Noh H1¹, Yu MR, Kim HJ, Jeon JS, Kwon SH, Jin SY, Lee J, Jang J, Park JO, Ziyadeh F, Han DC, Lee HB.

J Clin Oncol. 2012 Jan 20;30(3):268-73. doi: 10.1200/JCO.2011.39.1953. Epub 2011 Dec 19.

Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial

Lee J1¹, Lim do H, Kim S, Park SH, Park JO, Park YS, Lim HY, Choi MG, Sohn TS, Noh JH, Bae JM, Ahn YC, Sohn I, Jung SH, Park CK, Kim KM, Kang WK.

Salvage S-1 monotherapy in metastatic colorectal cancer patients who failed irinotecan-based or oxaliplatin-based chemotherapy

Transl Oncol.?2011 Dec;4(6):345-9. Epub 2011 Dec 1.

P21-Activated Kinase 4 Overexpression in Metastatic Gastric Cancer Patients

Ahn HK1¹,?Jang J,?Lee J,?Se Hoon P,?Park JO,?Park YS,?Lim HY,?Kim KM,?Kang WK.

Cancer?Chemother Pharmacol.?2011 Jul;68(1):255-62. doi: 10.1007/s00280-011-1653-5. Epub 2011 Apr 28.

Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer

Lim T1¹,?Lee J,?Lee DJ,?Lee HY,?Han B,?Baek KK,?Ahn HK,?Lee SJ,?Park SH,?Park JO,?Park YS,?Lim HY,?Kim KM,?Kang WK.

Oncol Rep.?2011 Jun;25(6):1517-24. doi: 10.3892/or.2011.1219. Epub 2011 Mar 18.

Impact of MET amplification on gastric cancer: Possible roles as a novel prognostic marker and a potential therapeutic target

Lee J1¹,?Seo JW,?Jun HJ,?Ki CS,?Park SH,?Park YS,?Lim HY,?Choi MG,?Bae JM,?Sohn TS,?Noh JH,?Kim S,?Jang HL,?Kim JY,?Kim KM,?Kang WK,?Park JO.

Melanoma?Res.?2011 Jun;21(3):223-7. doi: 10.1097/CMR.0b013e3283457743.

Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma: multicenter, retrospective analysis in Asia

Yi JH1¹,?Yi SY,?Lee HR,?Lee SI,?Lim do H,?Kim JH,?Park KW,?Lee J.

APMIS.?2011 Jun;119(6):330-5. doi: 10.1111/j.1600-0463.2011.02737.x. Epub 2011 Mar 24.

KIT amplification and gene mutations in acral/mucosal melanoma in Korea

Yun J1¹,?Lee J,?Jang J,?Lee EJ,?Jang KT,?Kim JH,?Kim KM.

J Natl Cancer Inst. 2011 Apr 20;103(8):674-88. doi: 10.1093/jnci/djr070. Epub 2011 Mar 11.

Effect of Simvastatin on Cetuximab Resistance in Human Colorectal Cancer With KRAS Mutations

Lee J1¹, Lee I, Han B, Park JO, Jang J, Park C, Kang WK.

Med Oncol.?2010 Dec;27(4):1149-54. doi: 10.1007/s12032-009-9351-4. Epub 2009 Nov 7.

The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater

Kim ST1¹,?Lee J,?Lee KT,?Lee JK,?Lee KH,?Choi SH,?Heo JS,?Choi DW,?Park SH,?Park JO,?Lim HY,?Park YS,?Kang WK.

Eur J Clin Pharmacol. 2010 Dec;66(12):1235-45. doi: 10.1007/s00228-010-0885-3. Epub 2010 Sep 9.

Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration

Ahn BJ1¹, Choi MK, Park YS, Lee J, Park SH, Park JO, Lim HY, Kang WK, Ko JW, Yim DS.

Chemotherapy.?2010;56(4):313-7. doi: 10.1159/000320032. Epub 2010 Aug 13.

Genetic Polymorphisms Associated with 5-Fluorouracil-Induced Neurotoxicity

Kim SR1¹,?Park CH,?Park S,?Park JO,?Lee J,?Lee SY.

J Thorac Oncol.?2010 Aug;5(8):1185-96. doi: 10.1097/JTO.0b013e3181e2f624.

Korean Ethnicity as Compared with White Ethnicity Is an Independent Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer before and after the Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Era

Ahn MJ1¹,?Lee J,?Park YH,?Ahn JS,?Ziogas A,?Zell JA,?Park K,?Ou SH.

Asia Pac J Clin Oncol.?2010 Jun;6(2):126-9. doi: 10.1111/j.1743-7563.2010.01278.x.

Extraosseous osteosarcoma: Single institutional experience in Korea

Lee S1¹,?Lee MR,?Lee SJ,?Ahn HK,?Yi J,?Yi SY,?Seo SW,?Sung KS,?Park JO,?Lee J.

Med Oncol.?2010 Jun;27(2):459-65. doi: 10.1007/s12032-009-9234-8. Epub 2009 May 27.

Expression of MET in alveolar soft part sarcoma

Jun HJ1¹,?Lee J,?Lim do H,?Park JO,?Ahn G,?Seo SW,?Sung KS,?Lim do H,?Yoo KH,?Choi YL.

Lung?Cancer.?2010 May;68(2):258-63. doi: 10.1016/j.lungcan.2009.06.008. Epub 2009 Jul 9.

Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases

Kim KH1¹,?Lee J,?Lee JI,?Nam do H,?Kong DS,?Ahn YC,?Park HC,?Kwon OJ,?Kim H,?Chang MH,?Yi SY,?Ji SH,?Park YH,?Ahn JS,?Park K,?Ahn MJ.

BMC Cancer.?2010 Apr 28;10:167. doi: 10.1186/1471-2407-10-167.

Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter study

Kim HS1¹,?Kim EK,?Jun HJ,?Oh SY,?Park KW,?Lim do H,?Lee SI,?Kim JH,?Kim KM,?Lee DH,?Lee J.

Echocardiography. 2010 Feb;27(2):E23-6. doi: 10.1111/j.1540-8175.2009.01059.x.

Primary Angiosarcoma of the Pulmonary Trunk Mimicking Pulmonary Thromboembolism

Kim JB1¹, Kim SH, Lim SY, Roh SY, Cho GY, Song HJ, Park S, Lee J, Kim SJ.

APMIS.?2009 Dec;117(12):861-9. doi: 10.1111/j.1600-0463.2009.02545.x.

Prognostic role of insulin-like growth factor receptor-1 expression in small cell lung cancer

Chang MH1¹,?Lee J,?Han J,?Park YH,?Ahn JS,?Park K,?Ahn MJ.

World J Gastroenterol. 2009 Oct 28;15(40):5086-90.

Gastric leptomeningeal carcinomatosis: Multi-center retrospective analysis of 54 cases

Oh SY1¹, Lee SJ, Lee J, Lee S, Kim SH, Kwon HC, Lee GW, Kang JH, Hwang IG, Jang JS, Lim HY, Park YS, Kang WK, Kim HJ.

Cancer Chemother Pharmacol. 2009 Sep;64(4):657-63. doi: 10.1007/s00280-008-0913-5. Epub 2009 Jan 24.

Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study

Lee J1¹, Jung KH, Park YS, Ahn JB, Shin SJ, Im SA, Oh do Y, Shin DB, Kim TW, Lee N, Byun JH, Hong YS, Park JO, Park SH, Lim HY, Kang WK.

APMIS. 2009 Aug;117(8):598-606. doi: 10.1111/j.1600-0463.2009.02512.x.

Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma

Lee J1¹, Kang WK, Park JO, Park SH, Park YS, Lim HY, Kim J, Kong J, Choi MG, Sohn TS, Noh JH, Bae JM, Kim S, Lim do H, Kim KM, Park CK.

BMC Cancer.?2009 Jun 26;9:205. doi: 10.1186/1471-2407-9-205.

Liposarcoma: exploration of clinical prognostic factors for risk based stratification of therapy

Kim HS1¹,?Lee J,?Yi SY,?Jun HJ,?Choi YL,?Ahn GH,?Seo SW,?Lim do H,?Ahn YC,?Park JO,?Kim SJ.

Cancer.?2009 Apr 1;115(7):1518-30. doi: 10.1002/cncr.24151.

Prognostic Model to Predict Outcomes in Nonsmall Cell Lung Cancer Patients Treated With Gefitinib as a Salvage Treatment

Park MJ1¹,?Lee J,?Hong JY,?Choi MK,?Yi JH,?Lee SJ,?Oh SJ,?Ahn JS,?Park K,?Ahn MJ.

Ann Oncol. 2008 Dec;19(12):2079-83. doi: 10.1093/annonc/mdn431. Epub 2008 Aug 9.

Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma

Lee J1¹, Suh C, Kang HJ, Ryoo BY, Huh J, Ko YH, Eom HS, Kim K, Park K, Kim WS.

Biol Blood Marrow Transplant.?2008 Dec;14(12):1356-64. doi: 10.1016/j.bbmt.2008.09.014.

Autologous Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T Cell Lymphoma: A Multinational, Multicenter, Matched Controlled Study

Lee J1¹,?Au WY,?Park MJ,?Suzumiya J,?Nakamura S,?Kameoka J,?Sakai C,?Oshimi K,?Kwong YL,?Liang R,?Yiu H,?Wong KH,?Cheng HC,?Ryoo BY,?Suh C,?Ko YH,Kim K,?Lee JW,?Kim WS,?Suzuki R.

Oncology.?2008;74 Suppl 1:4-6. doi: 10.1159/000143211. Epub 2008 Aug 28.

Progress of cancer pain management in Korea

Lee JY1¹,?Ahn JS.

Cancer Chemother Pharmacol.?2008 Jun;62(1):77-84. Epub 2007 Aug 31.

A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma

Lee J1¹,?Im YH,?Cho EY,?Hong YS,?Lee HR,?Kim HS,?Kim MJ,?Kim K,?Kang WK,?Park K,?Shim YM.

Cancer?Chemother Pharmacol.?2008 Apr;61(4):569-77. Epub 2007 May 17.

Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer

Lee J1¹,?Im YH,?Lee SH,?Cho EY,?Choi YL,?Ko YH,?Kim JH,?Nam SJ,?Kim HJ,?Ahn JS,?Park YS,?Lim HY,?Han BK,?Yang JH.

Cancer Chemother Pharmacol.?2008 Jan;61(1):47-52. Epub 2007 Mar 16.

Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas

Lee J1¹,?Kim TY,?Lee MA,?Ahn MJ,?Kim HK,?Lim HY,?Lee NS,?Park BJ,?Kim JS;?Korean Cancer Study Group.

Clin Cancer Res. 2008 Jan 1;14(1):82-8. doi: 10.1158/1078-0432.CCR-07-0612.

Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy

Lee J1¹, Park CK, Park JO, Lim T, Park YS, Lim HY, Lee I, Sohn TS, Noh JH, Heo JS, Kim S, Lim do H, Kim KM, Kang WK.

Cancer Lett. 2007 Dec 8;258(1):90-7.

Nongastric marginal zone B-cell lymphoma: A prognostic model from a retrospective multicenter study

Oh SY1¹, Kwon HC, Kim WS, Park YH, Kim K, Kim HJ, Kwon JM, Lee J, Ko YH, Ahn YC, Oh SJ, Lee SI, Bang SM, Kim JH, Park J, Ryoo BY, Lee SS, Kim HY, Park K, Kim HJ.

Clin Cancer Res.?2007 Jun 1;13(11):3250-4.

Effect of positive bone marrow EBV in situ hybridization in staging and survival of localized extranodal natural killer/T-cell lymphorna, nasal-type

Lee J1¹,?Suh C,?Huh J,?Jun HJ,?Kim K,?Jung C,?Park K,?Park YH,?Ko YH,?Kim WS.

Ann Oncol. 2007 May;18(5):886-91. Epub 2007 Feb 13.

Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma

Lee J1¹, Lim T, Uhm JE, Park KW, Park SH, Lee SC, Park JO, Park YS, Lim HY, Sohn TS, Noh JH, Heo JS, Park CK, Kim S, Kang WK.

J Gastroenterol Hepatol. 2006 Jun;21(6):999-1003.

Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplilications, and KRAS mutations on survival of pancreatic adenocarcinoma

Park BK1¹, Kim YJ, Park JY, Bang S, Park SW, Chung JB, Kim KS, Choi JS, Lee WJ, Song SY.

Leuk Res.?2007 Mar;31(3):359-64. Epub 2006 Aug 23.

Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphoma

Lee J1¹,?Kim WS,?Kim K,?Ahn JS,?Jung CW,?Lim HY,?Kang WK,?Park K,?Ko YH,?Kim YH,?Park C,?Yoon SH,?Lee WY,?Chun HK.

Ann Oncol. 2007 Jan;18(1):88-92. Epub 2006 Sep 13.

Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma

Lee J1¹, Kang WK, Kwon JM, Oh SY, Lee HR, Kim HJ, Park BB, Lim HY, Han MJ, Park JO, Park YS.

Pulmonary complications after hematopoietic stem cell transplantation

Oncol Rep.?2006 Jun;15(6):1541-9.

Interferon-alpha resistance can be reversed by inhibition of IFN-alpha-induced COX-2 expression potentially via STAT1 activation in A549 cells

Lee J1¹,?Jung HH,?Im YH,?Kim JH,?Park JO,?Kim K,?Kim WS,?Ahn JS,?Jung CW,?Park YS,?Kang WK,?Park K.

J Clin Oncol.?2006 Feb 1;24(4):612-8. Epub 2005 Dec 27.

Extranodal natural killer T-cell lymphoma, nasal-type: A prognostic model from a retrospective multicenter study

Lee J1¹,?Suh C,?Park YH,?Ko YH,?Bang SM,?Lee JH,?Lee DH,?Huh J,?Oh SY,?Kwon HC,?Kim HJ,?Lee SI,?Kim JH,?Park J,?Oh SJ,?Kim K,?Jung C,?Park K,?Kim WS.

Biochem Biophys Res Commun. 2006 Jan 20;339(3):748-54.

Lovastatin-induced RhoA modulation and its effect on senescence in prostate cancer cells

Lee J1¹, Lee I, Park C, Kang WK.

Cancer Chemother Pharmacol. 2006 Jan;57(1):91-6. Epub 2005 Nov 5.

Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer

Park SH1¹, Lee J, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Kang WK, Park K, Kim S, Bang SM, Cho EK, Shin DB, Lee JH.

Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1279-85. Epub 2005 Aug 15.

An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach

Kim S1¹, Lim DH, Lee J, Kang WK, MacDonald JS, Park CH, Park SH, Lee SH, Kim K, Park JO, Kim WS, Jung CW, Park YS, Im YH, Sohn TS, Noh JH, Heo JS, Kim YI, Park CK, Park K.

Ann Thorac Surg.?2005 Oct;80(4):1170-5.

Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma

Lee J1¹,?Lee KE,?Im YH,?Kang WK,?Park K,?Kim K,?Shim YM.

Biochem Biophys Res Commun.?2005 Aug 26;334(2):313-8.

Curcumin inhibits interferon-alpha induced NF-kappa B and COX-2 in human A549 non-small cell lung cancer cells

Lee J1¹,?Im YH,?Jung HH,?Kim JH,?Park JO,?Kim K,?Kim WS,?Ahn JS,?Jung CW,?Park YS,?Kang WK,?Park K.

Eur J Cancer.?2005 Jul;41(10):1402-8.

Extranodal nasal type NK/T-cell lymphoma: Elucidating clinical prognostic factors for risk-based stratification of therapy

Lee J1¹,?Park YH,?Kim WS,?Lee SS,?Ryoo BY,?Yang SH,?Park KW,?Kang JH,?Park JO,?Lee SH,?Kim K,?Jung CW,?Park YS,?Im YH,?Kang WK,?Lee MH,?Ko YH,?Ahn YC,?Park K.

Int J Hematol.?2005 Apr;81(3):258-63.

Influential factors for the collection of peripheral blood stem cells and engraftment in acute myeloid leukemia patients in first complete remission

Lee J1¹,?Lee MH,?Park KW,?Kang JH,?Im DH,?Kim K,?Lee SH,?Kim WS,?Park J,?Jung CW,?Parka K.

Br J Cancer.?2005 Apr 11;92(7):1226-30.

Nasal-type NK/T cell lymphoma: clinical features and treatment outcome

Lee J1¹,?Kim WS,?Park YH,?Park SH,?Park KW,?Kang JH,?Lee SS,?Lee SI,?Lee SH,?Kim K,?Jung CW,?Ahn YC,?Ko YH,?Park K.

Biol Blood Marrow Transplant. 2005 Feb;11(2):122-8.

Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission

Lee SH1¹, Lee MH, Lee JH, Min YH, Lee KH, Cheong JW, Lee J, Park KW, Kang JH, Kim K, Kim WS, Jung CW, Choi SJ, Lee JH, Park K.

Cancer Chemother Pharmacol.?2004 Nov;54(5):385-90. Epub 2004 Jul 10.

Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma

Lee J1¹,?Park JO,?Kim WS,?Park SH,?Park KW,?Choi MS,?Lee JH,?Koh KC,?Paik SW,?Yoo BC,?Joh J,?Kim K,?Jung CW,?Park YS,?Im YH,?Kang WK,?Lee MH,?Park K.

Leuk?Lymphoma.?2004 Feb;45(2):339-44.

Intestinal lymphoma: Exploration of the prognostic factors and the optimal treatment

Lee J1¹,?Kim WS,?Kim K,?Ko YH,?Kim JJ,?Kim YH,?Chun HK,?Lee WY,?Park JO,?Jung CW,?Im YH,?Lee MH,?Kang WK,?Park K.

Int J Hematol.?2004 Feb;79(2):185-8.

Tuberculosis in hematopoietic stem cell transplant recipients in Korea

Lee J1¹,?Lee MH,?Kim WS,?Kim K,?Park SH,?Lee SH,?Lee KE,?Park J,?Park JO,?Jung CW,?Im YH,?Kang WK,?Park K.

Oncology.?2004;66(1):32-7.

Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer

Lee J1¹,?Park JO,?Kim WS,?Lee SI,?Song SY,?Lim DH,?Choi SH,?Heo JS,?Lee KT,?Lee JK,?Kim K,?Jung CW,?Im YH,?Lee MH,?Kang WK,?Park K.